

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Prospective validation of the Cancer Ageing Research Group (CARG) score in geriatric patients undergoing curative intent chemotherapy: A simple assay to predict clinically relevant toxicity in the elderly

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-047376
Article Type:	Original research
Date Submitted by the Author:	30-Nov-2020
Complete List of Authors:	Ostwal, Vikas; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Medical Oncology Ramaswamy, Anant; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Bhargava, Prabhat; Tata Memorial Centre Hatkhambkar, Tejaswee; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Swami, Rohit; Narayana Multi speciality Hospital, Jaipur India. , Medical Oncology Rastogi, Sameer; AIIMS New Delhi, India. Mandavkar, Sarika; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Ghosh, Jaya; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Bajpai, Jyoti; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Gulia, Seema; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Srinivas, Sujay; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Rath, Sushmita; Tata Memorial Centre Gupta, Sudeep; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology
Keywords:	CHEMOTHERAPY, Adult oncology < ONCOLOGY, Gynaecological oncology < ONCOLOGY, Gastrointestinal tumours < ONCOLOGY, Breast tumours < ONCOLOGY, Adverse events < THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title – Prospective validation of the Cancer Ageing Research Group (CARG) score in geriatric patients undergoing curative intent chemotherapy: A simple assay to predict clinically relevant toxicity in the elderly

TITLE PAGE

Running title –CARG score in older Indian cancer patients undergoing curative-intent chemotherapy

Authors

1. Dr. Vikas Ostwal

Professor, Department of Medical Oncology,

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Email: dr.vikas.ostwal@gmail.com

2. Dr. Anant Ramaswamy

Associate Professor, Department of Medical Oncology,

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Email: anantr13@gmail.com

1
2
3 3. Dr Prabhat Bhargava
4

5
6 Assistant Professor, Department of Medical Oncology,
7

8
9 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

10
11 Email: bhargava611@gmail.com
12
13

14
15
16
17 4. Ms. Tejaswee Hatkhambkar
18

19
20 Research coordinator, Department of Medical Oncology,
21

22
23 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
24

25
26 Email: tejasweehatkambkar@gmail.com
27
28

29
30
31 5. Dr Rohit Swami
32

33
34 Assistant Professor, Department of Medical Oncology,
35

36
37 Narayana Multi speciality Hospital, Jaipur India.
38

39
40 Email: swamirohit21@yahoo.in
41
42

43
44
45 6. Dr Sameer Rastogi
46

47
48 Associate Professor, Department of Medical Oncology,
49

50
51 AIIMS New Delhi, India.
52

53
54 Email: samdoc_mamc@yahoo.com
55
56

57
58 7. Ms. Sarika Mandavkar
59
60

1
2
3 Research nurse, Department of Medical Oncology,
4

5
6 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
7

8
9 Email: sarikamandavkar1@gmail.com
10

11
12
13
14 8. Dr. Jaya Ghosh
15

16
17 Professor, Department of Medical Oncology,
18

19
20 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
21

22
23 Email: archana_jaya_ghosh@yahoo.co.in
24

25
26
27
28 9. Dr. Jyoti Bajpai
29

30
31 Professor, Department of Medical Oncology,
32

33
34 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
35

36
37 Email: dr_jyotibajpai@yahoo.co.in
38

39
40
41
42 10. Dr. Seema Gulia
43

44
45 Professor, Department of Medical Oncology,
46

47
48 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
49

50
51 Email: drseemagulia@gmail.com
52

53
54
55
56 11. Dr Sujay Srinivas
57

58
59 Assistant Professor, Department of Medical Oncology,
60

1
2
3 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
4
5

6 Email: sujay.0541@gmail.com
7
8
9

10
11 12. Dr Sushmita Rath
12

13
14 Assistant Professor, Department of Medical Oncology,
15

16
17 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
18

19
20 Email: sushmitarath73@gmail.com
21
22
23

24
25 13. Dr Sudeep Gupta
26

27
28 Professor, Department of Medical Oncology,
29

30
31 Director ACTREC, Room 309/310, 3rd Floor, Paymaster Shodhika,
32

33 ACTREC (Advanced Centre for Treatment, Research and Education in Cancer), Homi Bhabha
34

35 National Institute (HBNI), Navi Mumbai - 410210, Maharashtra, India
36

37
38 Email id - sudeepgupta04@yahoo.com
39
40
41
42

43 Corresponding author
44

45
46 Dr. Anant Ramaswamy
47

48
49 Associate Professor, Department of Medical Oncology,
50

51
52 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
53

54
55 Email: anantr13@gmail.com
56
57
58
59
60

1
2
3 Funding:

4
5
6 Received grants to Tata Memorial centre, Mumbai for the conduct of present study from

- 7
8
9 a. Indian Association of Supportive Care in Cancer awarded research award during BEST OF
10
11 MASCC 2019. **Grant number: 1716-A**
12
13
14 b. Intas pharmaceuticals private limited **Grant number: 1716-B**
15
16

17
18
19 Prior presentation: None
20

21
22 Conflict of interest: None
23

24
25 Author Contributions:

26
27 Conceptualization – Dr Vikas Ostwal , Dr Sudeep Gupta, Dr Sameer Rastogi, Dr Rohit Swami
28

29
30 Data curation – Dr Vikas Ostwal, Dr Anant Ramaswamy, Dr Prabhat Bhargava
31

32
33 Formal analysis – Dr Vikas Ostwal, Dr Anant Ramaswamy, Dr Prabhat Bhargava
34

35
36 Investigations - All authors
37

38
39 Project administration – All authors
40

41
42 Writing (original draft, review and editing) - All authors
43

44
45 Acknowledgements: Nil
46

47
48 Clinical trial registration: CTRI/2016/10/007357
49

50
51 Ethics committee Clearance: IEC/1019/1716/001
52

53
54 Word count: 2324
55
56
57
58
59
60

Abstract:**Importance:**

The Cancer Aging Research Group (CARG) toxicity score is used to assess toxicity risk in geriatric patients receiving chemotherapy.

Objective:

The primary aim was to validate the CARG score in geriatric patients treated with curative intent chemotherapy in predicting Grade 3-5 toxicities.

Design:

This was a longitudinal prospective observational study

Setting:

Tata Memorial Hospital, Mumbai, India, a tertiary cancer care referral centre.

Participants:

Patients age ≥ 65 with gastrointestinal, breast or gynaecological stage I-III cancers being planned for curative intent chemotherapy. A total of 270 patients were required for accrual in the study.

Exposure(s):

Total risk score ranged from 0 (lowest toxicity risk) to 19 (highest toxicity risk).

Main Outcome(s) and Measure(s):

The primary endpoint of the study was to evaluate whether the CARG risk score predicted for grade 3-5 toxicities.

Results:

The study cohort of 270 patients had a mean age of 69 years (65-83), with the most common cancers being gastrointestinal (79%). Fifty-two percent of patients had at-least one grade 3-5 toxicity. The risk of toxicity was increased with increasing risk score (42% low, 51% medium, 79% high risk; $P < .001$). There was no association between either ECOG PS ($p=0.69$) or age adjusted Charlson Comorbidity Index ($p=0.79$) risk categories and grade 3-5 chemotherapy toxicity.

Conclusions and Relevance:

The current study validates the CARG risk score in predicting for grade 3-5 toxicities in geriatric oncology patients receiving curative intent chemotherapy and can be considered as standard of care before planning chemotherapy in every elderly patient.

Key words – CARG risk; Hurria score, curative, ECOG PS, Charlson Comorbidity Index, chemotoxicity

1
2
3
4
5
6
7
8 **Strengths and limitations of the study:**
9

- 10 • The CARG risk score is a simple tool comprising easily available clinical information.
- 11
- 12 • This is a prospective study to assess CARG risk score in elderly patients treated with
- 13 curative intent to predict for grade 3-5 toxicities.
- 14
- 15 • CARG score performed better than traditional indices such as the age adjusted Charlson
- 16 Comorbidity Index and ECOG PS.
- 17
- 18 • The results suggest that the CARG score is valid in the studied population and can be
- 19 routinely used in clinical practice.
- 20
- 21 • This study does not include palliative patients and mainly GI cancer patients were
- 22 recruited.
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Manuscript :

Introduction

Older adult patients (age ≥ 65 years) with cancer represent a growing proportion of patients in community clinical practice, primarily due to increasing life-spans as well as medical progress contributing to decreased morbidity and mortality from other causes (1). Elderly patients comprise anywhere between 20% to 60% in community oncology practice, with variances based on access to cancer care, disease stage and centre specific management strategies (2,3).

The age adjusted Charlson Comorbidity Index (ACCI) and ECOG Performance status (PS) amongst others have often been used to quantify risks and predict for outcomes in older adults with cancer, but there is limited data for correlation between these indices and treatment related side effects (4–6). The Cancer Aging Research Group (CARG) risk score, developed by Hurria and colleagues, is an easy to use tool that predicts for significant chemotherapy related toxicities (grade 3- grade 5) in older North American adults ≥ 65 years starting on chemotherapy (7,8). Based on their training samples and subsequent validation studies, the investigators clearly identified low, mid and high-risk groups predicting for increasing rates of grade 3-5 toxicities (low risk: 30%, intermediate risk: 52%, high risk: 83%) with statistical significance ($P < 0.001$). The CARG risk score has been studied validated in other countries and in specific tumor sites to varying degrees (9,10).

In older adults being treated with curative intent chemotherapy, there is the possibility of treating oncologists using standard doses to maximize outcomes, despite patient related indicators suggesting a requirement for lower doses. This is a unique scenario where further information on risks and benefits would allow for informed clinical decision making on doses and drugs to be used. As patients with all stages of cancer were included in the CARG

1
2
3 studies, the ambiguity with regard to its usage in patients being treated with potentially
4
5 curative intent lends itself to re-examination.
6
7

8 With this background, the investigators conductive a longitudinal prospective study with the
9
10 primary aim of validating the CARG risk score in Indian older cancer patients treated with
11
12 curative intent chemotherapy (neoadjuvant or/and adjuvant chemotherapy). Secondary and
13
14 exploratory objectives included correlation of the age adjusted Charlson Comorbidity Index
15
16 (ACCI) and physician measured ECOG PS with grade 3-5 toxicities as well as an estimation
17
18 of grade 1 and grade 2 toxicities and their correlation with the CARG risk score.
19
20
21
22

23 **Materials and methods**

24 **Patient selection and design**

25
26
27 The study was designed as a longitudinal prospective observational study to validate the
28
29 CARG risk score in predicting chemotherapy toxicity risk in elderly patients. The study was
30
31 conducted at the Tata Memorial Hospital and enrolled patients aged ≥ 65 years,
32
33 chemotherapy naïve, with a histological diagnosis of gastrointestinal, breast or
34
35 gynaecological cancer, stage I-III disease and planned for neoadjuvant or adjuvant systemic
36
37 chemotherapy as a potentially curative treatment option.
38
39
40
41
42
43

44 The study was designed by investigators from the Department of Medical Oncology of the Tata
45
46 Memorial Hospital and was approved by the ethics committee (IEC/1019/1716/001). The study
47
48 was registered at Clinical trial registry of India (CTRI/2016/10/007357). Written informed
49
50 consent was obtained from all patients before inclusion in the study.
51
52
53

54 **Patient and public involvement:**

55
56
57 There was no public or patient involvement in design, conduct or results declaration of the
58
59 study.
60

Study procedures

Data regarding tumor type and stage, pre-treatment laboratory values, and chemotherapy regimen were recorded. All patients underwent standard pre-chemotherapy work up, including evaluation of end organ function. Patients were planned for chemotherapy by treating oncologist (with an assessment of ECOG PS and ACCI), who was blinded to the risk score. A study coordinator calculated the CARG risk score for patients enrolled in the study (7). Total risk score ranged from 0 (lowest toxicity risk) to 19 (highest toxicity risk), with division of the scores into low risk (0-5 points), intermediate risk (6 to 9 points) and high risk (10-19 points) as per the classification in the original study by Hurria et al (7). One modification of the original CARG risk score which was used in the current study was the measurement of 'Walking 1 block'. The concept of measuring distances by a block is not prevalent in India and hence, a distance of 100 metres in the immediate vicinity of the hospital was measured and patients were scored on their ability to walk the same. The chemotherapy dosing for the first cycle of chemotherapy was categorized as 'standard' if 100% doses were planned and 'dose reduced' if any dose below 100% was used. The decision for dose modifications was based on assessment by treating oncologist. Besides CARG risk score, the age adjusted Charlson's Comorbidity Index (ACCI) was calculated for all patients as part of standard assessment of older adults with cancer. A cut-off of 4 points (≤ 4 and > 4) was used to differentiate between low and high CCI scores (11). Patients were followed from beginning till the end of chemotherapy course. Toxicities were captured prospectively at all clinical visits (by treating oncologist and study coordinator) and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. Decision on relatedness of toxicity to chemotherapy was made by treating physician. Blood values were captured as grade 1 to 5 toxicity if they met the criteria

1
2
3 on the date of scheduled chemotherapy or at the time the patient was seeking attention
4
5 because of chemotherapy related toxicities.
6
7

8 Outcomes

9
10
11 The primary outcome of the study was the occurrence of any grade 3-5 chemotherapy related
12 toxicity over the course of planned treatment and its association with the CARG risk score.
13

14
15
16 The planned secondary endpoints of the study were the correlation of ACCI and ECOG PS
17 with grade 3-5 chemotherapy related toxicity. Occurrence of any grade 1-2 chemotherapy
18 related toxicity and its correlation with CARG risk score was an exploratory aspect of the
19 study.
20
21
22
23
24
25

26 Statistical analysis

27
28
29
30
31 Descriptive analyses were performed to enumerate patient, tumor, treatment characteristics,
32 CARG risk scores and ACCI. The incidence of grade 3 to grade 5 toxicities were calculated
33 and compared between CARG risk groups, and ECOG PS cohorts by using the chi-square
34 test. Sample size was calculated based on cumulative incidence of 20 % of grade 3-grade 5
35 toxicities in elderly patients with ECOG PS 0/1 and controlled or absent comorbidities as
36 opposed to 36% in elderly patients with ECOG PS 2 with or without multiple uncontrolled
37 comorbidities among patients receiving perioperative chemotherapy at Tata Memorial center
38 for breast, gastrointestinal and gynaecological cancers. A power of 80% and alpha of 5% with
39 1 sided assumption was required with estimated sample size required being 246 patients.
40
41
42 Assuming an attrition rate of 10%, a total of 270 patients were required for enrolment in the
43 study. Chi square test was performed to test the association of the CARG risk score, PS, and
44 ACCI with G 3-5 toxicities and for association of CARG risk score with grade 1-2 toxicities.
45
46
47 The predictive ability of the CARG risk score was evaluated by calculating receiver-
48
49
50
51
52
53
54
55
56
57
58
59
60

operating characteristic (ROC) curves and calculating the area under the curve (also known as C-statistic). ROC curves were also calculated for ECOG PS and ACCI. All analyses were performed using SPSS version 25. All tests were two-sided, and a P value of <0.05 was considered statistically significant.

Results

Patient and treatment characteristics

The study completed accrual of 270 patients, with mean age of patients being 69 years (range:65-83), 121 (45%) female patients and 212 patients (79%) having gastrointestinal cancers. For purposes of comparison, data from the seminal CARG study by Hurria et al is provided for comparison (table 1)

Chemotherapy toxicity

At least one grade 3 to 5 toxicity was seen in 140 patients (52%), with 119 (44%) having grade 3, 22 (8%) having grade 4, and 11(4%) grade 5 toxicities. Grade 3-5 haematological and non-haematological toxicities occurred in 60 patients (22%) and 120 (45%) patients respectively. Common haematological toxicities were neutropenia in 26 (10%) and febrile neutropenia in 17 (6%) patients, while common non-haematological toxicities were infections, fatigue and diarrhoea in 54 (20%), 24 (9%) and 23 (9%) patients respectively (table 2).

The incidence of grade 1 to grade 2 toxicities are listed in supplementary table 2.

CARG risk score and correlation with toxicity

The median overall CARG risk score was 6 (range, 0 to 19). Of the 270 patients, 72 (27%), 164 (61%) and 34 (13%) were classified as low, intermediate and high risk, respectively (table 1). Grade 3-5 toxicities were seen in 30(42%), 83 (51%) and 27 (79%) patients with

1
2
3 low, intermediate and high-risk score. There was a significant difference in toxicity amongst
4 the risk groups ($p<0.001$) (figure 1 and table 2). The odds of a patient classified as low risk
5 having a grade 3-5 toxicity as compared to patient with intermediate risk was 0.61 (95% CI:
6 0.47-0.81), while the odds of a patient classified as high risk having a grade 3-5 toxicity as
7 compared to patient with intermediate risk was 3.31 (95% CI:1.58-6.94). Area under the
8 ROC curve for the predictive model in the current cohort was 0.63 (95% CI: 0.57-0.7). The
9 correlation of individual components of the CARG risk score with grade 3-5 toxicities is
10 enumerated in supplementary table 1.
11
12
13
14
15
16
17
18
19
20
21

22 Grade 1-2 toxicities were seen in 61(86%), 144(88%) and 29 (85%) patients with low,
23 intermediate and high-risk score. There was no significant difference in toxicity amongst the
24 CARG risk groups ($p=0.79$).
25
26
27
28
29

30 Association of grade 3-5 toxicity with Age adjusted Charlson 31 Comorbidity Index (ACCI) and ECOG PS 32 33

34 The median ACCI was 5. A CCI \leq 4 was seen in 111 patients (41%), while 159 patients
35 (59%) had a CCI \geq 4. There was no significant difference in toxicities amongst both groups
36 of patients ($p=0.7$) (figure 1 and table 3). The ROC of the model with CCI (as a continuous
37 variable) was 0.48 (95% CI: 0.41-0.55), which was lower than the ROC of the CARG risk
38 score model, 0.63.
39
40
41
42
43
44
45
46

47 ECOG PS was 0, 1 and 2 in 9(3%), 221(82%) and 40 (15%) patients, respectively. There was
48 no significant difference in toxicities amongst both groups of patients ($p=0.69$) (figure 1 and
49 table 3). The ROC of the model with ECOG PS (as a continuous variable) was 0.52 (95% CI:
50 0.45-0.59), which was lower than the ROC of the CARG risk score model, 0.63.
51
52
53
54
55
56

57 Discussion 58 59 60

1
2
3 This study validates the CARG risk score in older Indian patients receiving curative-intent
4 chemotherapy for stage I-III gastrointestinal, breast and gynaecological cancers, though the
5 association between rates of severe chemotherapy toxicity and CARG risk groups as being
6 discriminatory was modest (AU-ROC 0.63). No association was found between ECOG PS
7 and burden of comorbidities as measured by the ACCI with severe chemotherapy related
8 toxicities.
9

10
11
12 There is a significant knowledge gap in terms of how older patients in general and older
13 patients with cancer fare in the Indian scenario. Limited data suggests no defined care
14 structure for older patients with cancer in India as well as only low-moderate awareness and
15 use of geriatric assessment in older patients with cancer (3,12) . Available evidence from
16 India suggests that 98% of older adult cancer patients have vulnerabilities in at least one
17 geriatric domain, though the specific vulnerabilities appear to differ from previously
18 published data (13). Such a high and differential vulnerability profile in these patients
19 suggests that they may have a different incidence of toxicities with standard chemotherapy
20 regimens. With such a background, it was essential to evaluate the validity of the CARG risk
21 score before routine advocacy in older adult patients.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40
41 There are some important differences between the populations of the current study and the
42 seminal CARG study. The current study had only patients with stage I-III disease, while the
43 CARG study had 38% with non-metastatic disease. Other relevant differences between the
44 cohorts include a younger mean age (69 vs. 73 years), lesser comorbidities (46% with no
45 comorbidities vs. 10% with no comorbidities), and better performance on a number of
46 individual variables in the CARG risk score (better hearing, lesser number of falls, better
47 social activity and effort tolerance). There were also a lower proportion of patients with high
48 risk score in the current study (13% vs. 22%). These differences indicate that patients in the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 current study were a well preserved and presumably fitter group of patients with lesser
4
5 disease burden and potential for toxicities.
6
7

8
9 Despite the differences in patient cohorts in terms of baseline characteristics, the current
10
11 study validated the Cancer Aging Research Group (CARG) risk score in predicting grade 3
12
13 to grade 5 chemotherapy related toxicities. The low, intermediate and high risk CARG groups
14
15 predicted for increasing incidences of grade 3-5 toxicities with statistical significance. The
16
17 odds ratios between individual risk groups for predicting grade 3-5 toxicity was also
18
19 statistically significant, highlighting the differential capability of the risk score. An
20
21 unanswered component of the CARG risk assessment was whether it correlated with grade 1-
22
23 2 toxicities. Previous studies by Moth et al estimating grade 1 and grade 2 toxicities as
24
25 toxicity burden have not shown a correlation with the CARG risk score (14). This is possibly
26
27 due to the near universal occurrence of such toxicities in patients receiving chemotherapy. A
28
29 similar trend was seen in the current study wherein an increasing risk score did not predict for
30
31 an increased risk of grade 1-2 toxicities. Additionally, in comparison to the predictive
32
33 capacity of the CARG risk score, the Charlson Comorbidity Index and ECOG PS based risk
34
35 groups did not predict for incidences of toxicity in the study. These results highlight certain
36
37 salient points in the study, Firstly, the CARG risk score can be used with confidence in the
38
39 Indian population to predict for grade 3-5 toxicity. The CARG risk score was evaluated only
40
41 in a North American elderly adult cohort initially and the current study provides validation
42
43 for the score in the Indian context. Secondly, despite being a better-preserved cohort in
44
45 comparison to the population in the seminal study as well as having only patients on curative
46
47 intent therapy, a high proportion of patients across risk groups developed grade 3-5 toxicity
48
49 which may be life-threatening. Thus, it is imperative to carefully assess the trade-off between
50
51 objectives such as survival and downstaging versus potentially life-threatening toxicities
52
53 while planning curative intent chemotherapy in older adult patients. Thirdly, the area under
54
55
56
57
58
59
60

1
2
3 the ROC for the current study was 0.63 and is lower in comparison to the original study
4 (0.72), though very similar to the results of the validation study (0.65) by the CARG group
5
6 (8). Though this indicates a modest discriminatory capability for the CARG risk score in the
7
8 current study, it is probably also reflective of the true value of the score in prediction of
9
10 severe chemotherapy related toxicities. Smaller studies by Australian investigators have also
11
12 previously commented on this lack of discriminatory value with the CARG risk score (14).
13
14 Finally, using a global assessment score such as ECOG PS or only one aspect of an
15
16 assessment profile such as comorbidity status (as in the case of ACCI) would not accurately
17
18 capture the heterogeneity of the older adult population. This is reflected in the inadequacy of
19
20 ECOG PS and ACCI in predicting for toxicities and hence, these indices should only be used
21
22 in conjunction with other indices as measures of assessment in older adults with cancer
23
24 (15,16).
25
26
27
28
29

30
31 Certain strengths of the current study need to be highlighted. The prospective collection of
32
33 toxicity data removes any recall bias that may lead to underestimation of the same. The
34
35 assessment in patients undergoing curative intent treatment only is novel and lays stress on
36
37 the conundrum faced by oncologists when balancing risks and benefits of using potentially
38
39 aggressive chemotherapy regimens in the neoadjuvant or adjuvant setting. The results will
40
41 allow patients and oncologists to discuss options with evidentiary basis for expected toxicities
42
43 when treatment regimens are considered. By validating the CARG risk score in an Indian
44
45 population, the study provides further evidence for the use of the score across geographical
46
47 regions.
48
49
50

51
52 There are certain limitations to this study. This is a single centre study and the results may not
53
54 be generalizable to practice across India. There is an under-representation of non-
55
56 gastrointestinal cancers and this may hamper the generalization of the study results to all
57
58 solid tumors. Additionally, other common solid tumors like lung cancers, head and neck
59
60

1
2
3 cancers and genitourinary cancers have not been evaluated in this study. The rate of grade 3-5
4
5 toxicities was much higher than planned as per baseline statistical considerations – this may
6
7 relate to the preponderance of GI cancers in the study population, besides other differences in
8
9 baseline characteristics of the patient cohorts as has been previously discussed. Additionally,
10
11 while information with regard to correlation of the CARG risk score with grade 1-2 toxicities
12
13 has been provided, the study was not statistically powered to provide an answer for the same.
14
15 We also do not have information on patient related outcomes in the study.
16
17
18
19

20
21 Going forward, future directions with regard to the CARG risk assessment include
22
23 developing paradigms for the degree of dose modifications required in patients based on the
24
25 score. Patients preferences with regard to tumor related endpoints versus toxicity limiting
26
27 QOL based on toxicity risk assessment can be explored in trials, especially in the advanced
28
29 cancer setting. Non-chemotherapeutic systemic treatment options like targeted therapy and
30
31 immunotherapy can be assessed by the risk score for predicting toxicity.
32
33

34
35 In conclusion, the current study validates the CARG risk score in predicting for grade 3-5
36
37 toxicities in Indian older adult cancer patients receiving curative intent chemotherapy. The
38
39 score contributes to informed clinical decision making with regard to planning treatment and
40
41 expectation of toxicity in this cohort of patients. Additionally, indices such as ECOG PS and
42
43 Charlson Comorbidity Index are inadequate to predict for toxicities and should only be used
44
45 along with other measures to predict for chemotherapy related toxicities.
46
47
48

49 References :

- 50
51
52 1. Marosi C, Köller M. Challenge of cancer in the elderly. ESMO Open. 2016 Apr
53
54 1;1(3): e000020.
55
56
57 2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010
58
59 Oct;60(5):277–300.
60

- 1
2
3 3. Patil VM, Chakraborty S, Dessai S, Kumar SS, Ratheesan K, Bindu T, et al. Patterns
4 of care in geriatric cancer patients – An audit from a rural based hospital cancer registry in
5 Kerala. *Indian J Cancer*. 2015 Jan 1;52(1):157.
6
7
- 8
9
10 4. Zhao L, Leung L-H, Wang J, Li H, Che J, Liu L, et al. Association between Charlson
11 comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung
12 cancer. *BMC Pulm Med* [Internet]. 2017 Aug 15 [cited 2020 Jun 17];17. Available from:
13 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556668/>
14
15
16
17
18
19
- 20 5. Edahyr B, Lind M, Karsera L, Mafi R, Wallace K, Howell G, et al. PUB068 The
21 Applicability of Comorbidity Indices in Predicting Chemo toxicity in Non-Small Cell Lung
22 Cancer. *J Thorac Oncol*. 2017 Jan 1;12(1): S1487–8.
23
24
25
26
27
- 28 6. van Abbema DL, van den Akker M, Janssen-Heijnen ML, van den Berkmortel F,
29 Hoeben A, de Vos-Geelen J, et al. Patient- and tumor-related predictors of chemotherapy
30 intolerance in older patients with cancer: A systematic review. *J Geriatr Oncol*. 2019 Jan
31 1;10(1):31–41.
32
33
34
35
36
37
- 38 7. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting
39 Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. *J*
40 *Clin Oncol*. 2011 Sep 1;29(25):3457–65.
41
42
43
44
45
- 46 8. Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a
47 Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. *J Clin Oncol*. 2016
48 May 16;34(20):2366–71.
49
50
51
52
- 53 9. Nie X, Liu D, Li Q, Bai C. Predicting chemotherapy toxicity in older adults with lung
54 cancer. *J Geriatr Oncol*. 2013 Oct 1;4(4):334–9.
55
56
57
58
59
60

10. Alibhai SMH, Aziz S, Manokumar T, Timilshina N, Breunis H. A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer. *J Geriatr Oncol*. 2017;8(1):31–6.
11. Yang C-C, Fong Y, Lin L-C, Que J, Ting W-C, Chang C-L, et al. The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices. *Eur J Cardiothorac Surg*. 2018 Jan 1;53(1):235–40.
12. Noronha V, Talreja V, Joshi A, Patil V, Prabhash K. Survey for geriatric assessment in practicing oncologists in India. *Cancer Res Stat Treat*. 2019 Jul 1;2(2):232.
13. Noronha V, Ramaswamy A, Dhekle R, Talreja V, Gota V, Gawit K, et al. Initial experience of a geriatric oncology clinic in a tertiary cancer center in India. *Cancer Res Stat Treat*. 2020 Jul 1;3(2):208.
14. Moth EB, Kiely BE, Stefanic N, Naganathan V, Martin A, Grimison P, et al. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. *J Geriatr Oncol*. 2019;10(2):202–9.
15. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. *Cancer*. 2012;118(13):3377–86.
16. Zhang J, Liao X, Feng J, Yin T, Liang Y. Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology. *Oncol Lett*. 2019 Oct 31;18(5):4947–55.

Figure legends:

Figure 1- CARG (A) vs. (B) ACCI vs. (C) ECOG PS predict Grade 3 to 5 toxicity

Tables

Table 1 - Baseline characteristics of patients

Characteristic	Current study Number (%) (n=270)	CARG training cohort (n=500)
Mean age in years (range)	69 (65-83)	73 (65-91)
Gender <ul style="list-style-type: none"> Female Male 	121 (45) 149 (55)	281 (56) 219 (44)
Comorbidities <ul style="list-style-type: none"> Hypertension Diabetes mellitus Coronary artery disease Chronic kidney disease 	114 (42) 71 (26) 12 (4) 3 (1)	52% - 20% -
Number of comorbidities <ul style="list-style-type: none"> 0 1 >=2 	125 (46) 95 (35) 50 (19)	10% - -
Cancer stage <ul style="list-style-type: none"> Stage I-III 	270 (100)	191 (38)
Undergone resection	210 (78)	-
ECOG performance status (clinician assessed) <ul style="list-style-type: none"> 0/1 2 	230 (85) 40 (15)	402 (80) * 86 (17) **

Factors assessed in CARG <ul style="list-style-type: none"> • Age \geq 72 years • Cancer type GI or GU • Chemotherapy dosing, standard dose • No. of chemotherapy drugs, polychemotherapy • Haemoglobin < 11 g/dL (male), < 10 g/dL (female) • Creatinine clearance < 34 mL/min • Hearing, fair or worse • No. of falls in last 6 months, 1 or more • IADL: Taking medications, with some help/unable • MOS: Walking 1 block, somewhat limited/limited a lot • MOS: Decreased social activity because of physical/emotional health, limited at least sometimes 	60 (22) 212 (79) 205 (76) 194 (72) 99 (37) 5 (2) 19 (7) 18 (7) 29 (11) 17 (6) 18 (7)	270 (54) 185 (37) 380 (76) 351 (70) 62 (12) 44 (9) 123 (25) 91 (18) 39 (8) 109 (22) 218 (44)
Median overall risk score Risk stratification <ul style="list-style-type: none"> • Low risk (0-5 points) • Intermediate risk (6-9 points) • High risk (10-19 points) 	6 72 (27) 164 (61) 34 (13)	7 128 (26) 227 (45) 109 (22)
Age adjusted Charlson's Comorbidity Index <ul style="list-style-type: none"> • \leq4 • >4 	111(41) 159(59)	- -

*equivalent to KPS \geq 80; ** equivalent to KPS 60-70

Table 2 – Treatment related Grade 3 – grade 5 toxicities

Toxicity type	Grade 3 (%)	Grade 4 (%)	Grade 5 (%)
Haematological			
Anaemia	14 (5)	0	0
Neutropenia	18 (7)	8(3)	0
Thrombocytopenia	6 (2)	1 (0.4)	0
Febrile neutropenia	12 (4)	2 (0.7)	3(1)
Cumulative haematological	46 (17)	11 (4)	3(1)
Non-haematological			
Diarrhoea	16 (6)	4 (2)	3(1) *
Vomiting	12 (4)	1(0.4)	1(0.3) **
Mucositis	10 (4)	0	
Constipation	1 (0.4)	0	
Hand-foot-syndrome	1 (0.4)	-	
Neuropathy	3 (1)	-	
Infection with normal ANC	47 (17)	7(3)	
Hyponatremia	8 (3)	2 (0.7)	
Fatigue	24 (9)	-	
Sudden cardiac death			4(1)
Cumulative non-haematological	99(37)	13(5)	8(3)
Cumulative (all toxicities)	119(44)	22(8)	11(4)

*All 3 patients developed dehydration with resulting acute renal failure. **Patient developed grade 4 vomiting with irreversible grade 4 hyponatremia resulting in death

Table 3 - Ability of CARG Risk Score Versus Physician assessed ECOG PS Versus Age adjusted Charlson's Comorbidity Index (ACCI) to Predict Grade 3-5 Chemotherapy Toxicity

Risk Stratification	No toxicity		Toxicity		p value
	Number	%	Number	%	
CARG risk score					
• Low	42	58	30	42	0.001
• Intermediate	81	49	83	51	
• High	7	21	27	79	
Physician assessed ECOG PS					
• 0	5	56	4	44	0.69
• 1	108	49	113	51	
• 2	17	43	23	57	
Age adjusted Charlson's Comorbidity Index					
• ≤4	55	50	56	50	0.7
• >4	75	47	84	53	

Figure 1 – Ability of CARG risk score (A) versus (B) Age adjusted Charlson Comorbidity Index (ACCI) versus (C) ECOG Performance Status Index to predict Grade 3 to 5 chemotherapy toxicity.




Figure 1- CARG (A) vs. (B) ACCI vs. (C) ECOG PS predict Grade 3 to 5 toxicity

215x279mm (300 x 300 DPI)

Supplementary table 1 – Treatment- related Grade 1 – grade 2 toxicities

Toxicity type	Grade 1/2 toxicities (%)
Haematological	
Anaemia	148(55)
Neutropenia	52(19)
Cumulative haematological	160(59)
Non-haematological	
Diarrhoea	131(49)
Vomiting	140(52)
Mucositis	57(21)
Constipation	41(15)
Hand-foot-syndrome	59(22)
Neuropathy	75(28)
Hyponatremia	17(6)
Fatigue	197(73)
Cumulative non-haematological	230(85)
Cumulative (all toxicities)	234(87)

Supplementary table 2 - Ability of individual factors in the CARG risk score to predict for Grade 3 to 5 toxicities

Risk factor	Prevalence		Toxicity		p value	OR (95% CI)
	Number	%	Number	%		
Age \geq 72 years	60	22	34	57	0.4	1.28 (0.72-2.29)
Cancer type (GI or GU)	212	79	116	55	0.07	1.71 (0.95-3.08)
Chemotherapy dosing, standard dose	201	74	101	50	0.37	0.77 (0.45-1.35)
Polychemotherapy	194	72	106	55	0.14	1.48 (0.87-2.54)
Haemoglobin $<$ 11gm% (male), $<$ 10gm% (female)	99	37	65	66	0.001	2.45(1.47-4.09)
Creatinine clearance $<$ 34ml/min	5	2	3	60	0.71	1.4(0.23-8.52)
Hearing, fair or worse	19	7	10	53	0.94	1.03(0.41-2.63)
No. of falls in last 6 months, \geq 1	18	7	10	56	0.75	1.17(0.45-3.07)
IADL, taking medications, with some help/unable	29	11	17	59	0.44	1.336 (0.62-2.97)
MOS, walking 1 block equivalent, somewhat limited/limited a lot	17	6	11	65	0.27	1.76 (0.63-4.91)
MOS, decreased social activity because of physical/emotional health, limited at least sometimes	18	7	12	67	0.19	1.94(0.71-5.32)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Precis

The CARG risk score was studied prospectively in older adult cancer patients being treated with curative intent and accurately predicts for grade 3-5 toxicities. The score can be incorporated into clinical decision making for older adults with cancer, and performed better than traditional indices such as the age adjusted Charlson Comorbidity Index and ECOG PS.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	6
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	9
Objectives	3	State specific objectives, including any prespecified hypotheses	10
Methods			
Study design	4	Present key elements of study design early in the paper	10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	10
		(b) For matched studies, give matching criteria and number of exposed and unexposed	10
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11
Bias	9	Describe any efforts to address potential sources of bias	12
Study size	10	Explain how the study size was arrived at	12
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	12
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	12
		(b) Describe any methods used to examine subgroups and interactions	12
		(c) Explain how missing data were addressed	12
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			13

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	13
		(b) Give reasons for non-participation at each stage	13
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13
		(b) Indicate number of participants with missing data for each variable of interest	13
		(c) Summarise follow-up time (eg, average and total amount)	13
Outcome data	15*	Report numbers of outcome events or summary measures over time	14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14
Discussion			
Key results	18	Summarise key results with reference to study objectives	15
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	5

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prospective validation of the Cancer Ageing Research Group (CARG) score in geriatric patients undergoing curative intent chemotherapy: A simple assay to predict clinically relevant toxicity in the elderly

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-047376.R1
Article Type:	Original research
Date Submitted by the Author:	14-Mar-2021
Complete List of Authors:	Ostwal, Vikas; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Medical Oncology Ramaswamy, Anant; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Bhargava, Prabhat; Tata Memorial Centre Hatkhambkar, Tejaswee; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Swami, Rohit; Narayana Multi speciality Hospital, Jaipur India. , Medical Oncology Rastogi, Sameer; AIIMS New Delhi, India. Mandavkar, Sarika; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Ghosh, Jaya; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Bajpai, Jyoti; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Gulia, Seema; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Srinivas, Sujay; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Rath, Sushmita; Tata Memorial Centre Gupta, Sudeep; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology
Primary Subject Heading:	Geriatric medicine
Secondary Subject Heading:	Oncology, Pharmacology and therapeutics, Medical management, Geriatric medicine, Health services research
Keywords:	CHEMOTHERAPY, Adult oncology < ONCOLOGY, Gynaecological oncology < ONCOLOGY, Gastrointestinal tumours < ONCOLOGY, Breast tumours < ONCOLOGY, Adverse events < THERAPEUTICS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title – Prospective validation of the Cancer Ageing Research Group (CARG) score in geriatric patients undergoing curative intent chemotherapy: A simple assay to predict clinically relevant toxicity in the elderly

TITLE PAGE

Running title –CARG score in older Indian cancer patients undergoing curative-intent chemotherapy

Authors

1. Dr. Vikas Ostwal

Professor, Department of Medical Oncology,

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Email: dr.vikas.ostwal@gmail.com

2. Dr. Anant Ramaswamy

Associate Professor, Department of Medical Oncology,

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Email: anantr13@gmail.com

1
2
3 3. Dr Prabhat Bhargava
4

5
6 Assistant Professor, Department of Medical Oncology,
7

8
9 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

10
11 Email: bhargava611@gmail.com
12
13

14
15
16
17 4. Ms. Tejaswee Hatkhambkar
18

19
20 Research coordinator, Department of Medical Oncology,
21

22
23 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
24

25
26 Email: tejasweehatkambkar@gmail.com
27
28

29
30
31 5. Dr Rohit Swami
32

33
34 Assistant Professor, Department of Medical Oncology,
35

36
37 Narayana Multi specialty Hospital, Jaipur India.
38

39
40 Email: swamirohit21@yahoo.in
41
42

43
44
45 6. Dr Sameer Rastogi
46

47
48 Associate Professor, Department of Medical Oncology,
49

50
51 AIIMS New Delhi, India.
52

53
54 Email: samdoc_mamc@yahoo.com
55
56

57
58 7. Ms. Sarika Mandavkar
59
60

1
2
3 Research nurse, Department of Medical Oncology,
4

5
6 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
7

8
9 Email: sarikamandavkar1@gmail.com
10
11
12
13

14 8. Dr. Jaya Ghosh
15

16
17 Professor, Department of Medical Oncology,
18

19
20 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
21

22
23 Email: archana_jaya_ghosh@yahoo.co.in
24
25
26
27

28 9. Dr. Jyoti Bajpai
29

30
31 Professor, Department of Medical Oncology,
32

33
34 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
35

36
37 Email: dr_jyotibajpai@yahoo.co.in
38
39
40
41

42 10. Dr. Seema Gulia
43

44
45 Professor, Department of Medical Oncology,
46

47
48 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
49

50
51 Email: drseemagulia@gmail.com
52
53
54
55

56 11. Dr Sujay Srinivas
57

58
59 Assistant Professor, Department of Medical Oncology,
60

1
2
3 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
4
5

6 Email: sujay.0541@gmail.com
7
8
9

10
11 12. Dr Sushmita Rath
12

13
14 Assistant Professor, Department of Medical Oncology,
15

16
17 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
18

19
20 Email: sushmitarath73@gmail.com
21
22
23

24
25 13. Dr Sudeep Gupta
26

27
28 Professor, Department of Medical Oncology,
29

30
31 Director ACTREC, Room 309/310, 3rd Floor, Paymaster Shodhika,
32

33 ACTREC (Advanced Centre for Treatment, Research and Education in Cancer), Homi Bhabha
34

35 National Institute (HBNI), Navi Mumbai - 410210, Maharashtra, India
36

37
38 Email id - sudeepgupta04@yahoo.com
39
40
41
42

43 Corresponding author
44

45
46 Dr. Anant Ramaswamy
47

48
49 Associate Professor, Department of Medical Oncology,
50

51
52 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
53

54
55 Email: anantr13@gmail.com
56
57
58
59
60

Funding:

Received grants to Tata Memorial centre, Mumbai for the conduct of present study from

- a. Indian Association of Supportive Care in Cancer awarded research award during BEST OF MASCC 2019. **Grant number: 1716-A**
- b. Intas Pharmaceuticals Private Limited **Grant number: 1716-B – The Pharmaceutical company, Intas Pharmaceutical Private Limited, provided an unrestricted educational grant to Tata Memorial Centre (The Institute) for the conduct of the study. This was utilized for appointing a trained medical doctor for the purpose of the study.**

Prior presentation: None

Conflict of interest: None

Author Contributions:

1. Dr. Vikas Ostwal

Author contribution - Conception and design, analysis and interpretation of data, drafting of manuscript, Final approval of the submitted version.

2. Dr. Anant Ramaswamy

Author contribution - Conception and design, analysis and interpretation of data, drafting of manuscript, Final approval of the submitted version.

3. Dr Prabhat Bhargava

Author contribution - analysis and interpretation of data, drafting of manuscript, Final approval of the submitted version.

4. Ms. Tejaswee Hatkhambkar

1
2
3 Author contribution - analysis and interpretation of data, Final approval of the
4
5 submitted version.
6
7

8 5. Dr Rohit Swami
9

10 Author contribution - analysis and interpretation of data, drafting of manuscript,
11
12 Final approval of the submitted version.
13
14

15 6. Dr Sameer Rastogi
16

17 Author contribution - Conception and design, drafting of manuscript, Final approval
18
19 of the submitted version.
20
21

22 7. Ms. Sarika Mandavkar
23

24 Author contribution - analysis and interpretation of data, drafting of manuscript,
25
26 Final approval of the submitted version.
27
28

29 8. Dr. Jaya Ghosh
30

31 Author contribution - analysis and interpretation of data, drafting of manuscript,
32
33 Final approval of the submitted version.
34
35

36 9. Dr Sushmita Rath
37

38 Author contribution - analysis and interpretation of data, drafting of manuscript,
39
40 Final approval of the submitted version.
41
42

43
44
45 10. Dr. Jyoti Bajpai
46

47 Author contribution - analysis and interpretation of data, drafting of manuscript,
48
49 Final approval of the submitted version.
50
51

52 11. Dr. Seema Gulia
53

54 Author contribution - analysis and interpretation of data, drafting of manuscript,
55
56 Final approval of the submitted version.
57
58
59
60

1
2
3
4
5
6
7
12. Dr Sujay Srinivas

8 Author contribution - analysis and interpretation of data, drafting of manuscript,

9
10 Final approval of the submitted version.
11
12
13
14

15
16
17
18
19
20
21
22
13. Dr Sudeep Gupta

17 Author contribution - Conception and design, analysis and interpretation of data,

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
drafting of manuscript, Final approval of the submitted version.

23 Acknowledgements: Nil

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Clinical trial registration: CTRI/2016/10/007357

28 Ethics committee Clearance:

- 31 1. Name of the Ethics committee: Institutional Ethics committee, Tata Memorial Centre,
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Parel, Mumbai.
- 37 2. IEC approval ID: IEC/1019/1716/001
- 40 3. The participants gave informed consent before taking part in the study.

43 Word count: 3398 (excluding abstract and references)

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Data Availability statement: Data are available upon reasonable request

1
2
3 **Abstract:**
4

5 **Importance:**
6

7
8 The Cancer Aging Research Group (CARG) toxicity score is used to assess toxicity risk in
9
10 geriatric patients receiving chemotherapy.
11

12
13 **Objective:**
14

15
16 The primary aim was to validate the CARG score in geriatric patients treated with curative
17
18 intent chemotherapy in predicting Grade 3-5 toxicities.
19

20
21 **Design:**
22

23
24 This was a longitudinal prospective observational study
25

26
27 **Setting:**
28

29
30 Tata Memorial Hospital, Mumbai, India, a tertiary cancer care referral centre.
31

32
33 **Participants:**
34

35
36 Patients age ≥ 65 with gastrointestinal, breast or gynaecological stage I-III cancers being
37
38 planned for curative intent chemotherapy. A total of 270 patients were required for accrual in
39
40 the study.
41

42
43 **Exposure(s):**
44

45
46 Total risk score ranged from 0 (lowest toxicity risk) to 19 (highest toxicity risk).
47

48
49 **Main Outcome(s) and Measure(s):**
50

51
52 The primary endpoint of the study was to evaluate whether the CARG risk score predicted for
53
54 grade 3-5 toxicities.
55

56
57 **Results:**
58
59
60

1
2
3 The study cohort of 270 patients had a mean age of 69 years (65-83), with the most common
4 cancers being gastrointestinal (79%). Fifty-two percent of patients had at-least one grade 3-5
5 toxicity. The risk of toxicity was increased with increasing risk score (42% low, 51%
6 medium, 79% high risk; $P < .001$). There was no association between either ECOG PS
7 (p=0.69) or age adjusted Charlson Comorbidity Index (p=0.79) risk categories and grade 3-5
8 chemotherapy toxicity.
9
10
11
12
13
14
15
16

17 **Conclusions and Relevance:**

18
19
20 The current study validates the CARG risk score in predicting for grade 3-5 toxicities in
21 geriatric oncology patients receiving curative intent chemotherapy and can be considered as
22 standard of care before planning chemotherapy in every elderly patient.
23
24
25
26
27
28
29
30

31 **Key words** – CARG risk; Hurria score, curative, ECOG PS, Charlson Comorbidity Index,
32 chemotoxicity
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of the study:

- The CARG risk score is a simple tool comprising easily available clinical information.
- This is a prospective study to assess CARG risk score in elderly patients treated with curative intent to predict for grade 3-5 toxicities.
- CARG score performed better than traditional indices such as the age adjusted Charlson Comorbidity Index and ECOG PS.
- The results suggest that the CARG score is valid in the studied population and can be routinely used in clinical practice.
- This study does not include palliative patients and mainly GI cancer patients were recruited.

Manuscript:**Introduction**

Older adult patients (age ≥ 65 years) with cancer represent a growing proportion of patients in community clinical practice, primarily due to increasing life-spans as well as medical

1
2
3 progress contributing to decreased morbidity and mortality from other causes (1). Elderly
4 patients comprise anywhere between 20% to 60% in community oncology practice, with
5
6 variances based on access to cancer care, disease stage and centre specific management
7
8 strategies (2,3).
9

10
11
12
13 The age adjusted Charlson Comorbidity Index (ACCI) and ECOG Performance status (PS)
14 amongst others have often been used to quantify risks and predict for outcomes in older
15
16 adults with cancer, but there is limited data for correlation between these indices and
17
18 treatment related side effects (4–6). The Cancer Aging Research Group (CARG) risk score,
19
20 developed by Hurria and colleagues, is an easy-to-use tool that predicts for significant
21
22 chemotherapy related toxicities (grade 3- grade 5) in older North American adults ≥ 65
23
24 years starting on chemotherapy (7,8). Based on their training samples and subsequent
25
26 validation studies, the investigators clearly identified low, mid and high-risk groups
27
28 predicting for increasing rates of grade 3-5 toxicities (low risk: 30%, intermediate risk: 52%,
29
30 high risk: 83%) with statistical significance ($P < 0.001$). The CARG risk score has been
31
32 validated in other countries and in specific tumor sites to varying degrees (9,10).
33
34
35
36
37
38

39 In older adults being treated with curative intent chemotherapy, there is the possibility of
40
41 treating oncologists using standard doses to maximize outcomes, despite patient related
42
43 indicators suggesting a requirement for lower doses. This is a unique scenario where further
44
45 information on risks and benefits would allow for informed clinical decision making on doses
46
47 and drugs to be used. As patients with all stages of cancer were included in the CARG
48
49 studies, the ambiguity with regard to its usage in patients being treated with potentially
50
51 curative intent lends itself to re-examination.
52
53
54

55
56 With this background, the investigators conducted a longitudinal prospective study with the
57
58 primary aim of validating the CARG risk score in Indian older cancer patients treated with
59
60

1
2
3 curative intent chemotherapy (neoadjuvant or/and adjuvant chemotherapy). Secondary and
4
5 objectives included correlation of the age adjusted Charlson Comorbidity Index (ACCI) and
6
7 physician measured ECOG PS with grade 3-5 toxicities. An exploratory component of the
8
9 study involved an estimation of grade 1 and grade 2 toxicities and their correlation with the
10
11 CARG risk score.
12
13

14 15 **Materials and methods**

16 17 **Patient selection and design**

18
19
20 The study was designed as a longitudinal prospective observational study to validate the
21
22 CARG risk score in predicting chemotherapy toxicity risk in elderly patients. The study was
23
24 conducted at the Tata Memorial Hospital and enrolled consecutive patients aged ≥ 65 years,
25
26 chemotherapy naïve, with a histological diagnosis of gastrointestinal, breast or gynecological
27
28 cancer, stage I-III disease and planned for neoadjuvant or adjuvant systemic chemotherapy as
29
30 a potentially curative treatment option.
31
32

33
34
35 The study was designed by investigators from the Department of Medical Oncology of the Tata
36
37 Memorial Hospital and was approved by the ethics committee (IEC/1019/1716/001). The study
38
39 was registered at Clinical trial registry of India (CTRI/2016/10/007357). Written informed
40
41 consent was obtained from all patients before inclusion in the study.
42
43
44
45

46 47 **Patient and public involvement:**

48
49
50 There was no public or patient involvement in design, conduct or results declaration of the
51
52 study.
53
54
55
56
57
58
59
60

Study procedures

Data regarding tumor type and stage, pre-treatment laboratory values, and chemotherapy regimen were recorded. All patients underwent standard pre-chemotherapy work up, including evaluation of end organ function. Patients were planned for chemotherapy by treating oncologist (with an assessment of ECOG PS and ACCI), who was blinded to the risk score. A trained medical doctor calculated the CARG risk score for patients enrolled in the study. The assessment of the score by the trained medical doctor was independently reviewed by an oncologist who was not part of the treating team (7). Total risk score ranged from 0 (lowest toxicity risk) to 19 (highest toxicity risk), with division of the scores into low risk (0-5 points), intermediate risk (6 to 9 points) and high risk (10-19 points) as per the classification in the original study by Hurria et al (7). One modification of the original CARG risk score which was used in the current study was the measurement of 'Walking 1 block'. The concept of measuring distances by a block is not prevalent in India and hence, a distance of 100 meters in the immediate vicinity of the hospital was measured and patients were scored on their ability to walk the same. The chemotherapy dosing for the first cycle of chemotherapy was categorized as 'standard' if 100% doses were planned and 'dose reduced' if any dose below 100% was used. The decision for dose modifications, whether initial or subsequent, was based on assessment by treating oncologist. Besides CARG risk score, the age adjusted Charlson's Comorbidity Index (ACCI) was calculated for all patients as part of standard assessment of older adults with cancer. A cut-off of 4 points (≤ 4 and >4) was used to differentiate between low and high CCI scores (11). Patients were followed from beginning till the end of chemotherapy course across all cycles of therapy, though occurrence of a single grade 3-4 toxicity was considered as an endpoint for the purpose of toxicity calculation in the study. Toxicities were captured prospectively at all clinical visits (by treating oncologist and trained medical doctor) and graded as per National Cancer Institute

1
2
3 Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. Decision on
4 relatedness of toxicity to chemotherapy was made by treating physician. Laboratory values
5 were captured as grade 1 to 5 toxicity if they met the criteria on the date of scheduled
6 chemotherapy or when patient was seeking attention because of treatment related toxicities.
7
8
9
10
11
12

13 Outcomes

14
15
16 The primary outcome of the study was the occurrence of any grade 3-5 chemotherapy related
17 toxicity over the course of planned treatment and its association with the CARG risk score.
18
19 The planned secondary endpoints of the study were the correlation of ACCI and ECOG PS
20 with grade 3-5 chemotherapy related toxicity. Occurrence of any grade 1-2 chemotherapy
21 related toxicity and its correlation with CARG risk score was an exploratory aspect of the
22 study.
23
24
25
26
27
28
29
30

31 Statistical analysis

32
33
34
35 Descriptive analyses were performed to enumerate patient, tumor, treatment characteristics,
36 CARG risk scores and ACCI. The incidence of grade 3 to grade 5 toxicities were calculated
37 and compared between CARG risk groups, and ECOG PS cohorts by using the chi-square
38 test. The CARG risk score is not routinely used in clinical practice in our institution and we
39 did not have baseline data for the same for the purpose of sample size calculation . We
40 conducted an internal audit of elderly patients with breast, gastrointestinal and gynecological
41 cancers receiving curative intent chemotherapy in our hospital and found a 20 % incidence
42 of grade 3-grade 5 toxicities in elderly patients with ECOG PS 0/1 and controlled or absent
43 comorbidities (surrogate for “low risk) as opposed to 36% in elderly patients with ECOG PS
44 2 with or without multiple uncontrolled comorbidities (surrogate for “ high risk”).
45
46
47
48
49
50
51
52
53
54
55
56
57
58 Extrapolating these results, a power of 80% and alpha of 5% with 1 sided assumption was
59
60

1
2
3 required with an estimated sample size required being 246 patients. Assuming an attrition rate
4
5 of 10%, a total of 270 patients were required for enrolment in the study. Chi square test was
6
7 performed to test the association of the CARG risk score, PS, and ACCI with G 3-5 toxicities
8
9 and for association of CARG risk score with grade 1-2 toxicities as well dose modifications.
10
11 The predictive ability of the CARG risk score was evaluated by calculating receiver-
12
13 operating characteristic (ROC) curves and calculating the area under the curve (also known
14
15 as C-statistic). ROC curves were also calculated for ECOG PS and ACCI. All analyses were
16
17 performed using SPSS version 25. All tests were two-sided, and a P value of <0.05 was
18
19 considered statistically significant.
20
21
22
23

24 25 Results

26 27 28 Patient and treatment characteristics

29
30 The study completed accrual of 270 patients, with mean age of patients being 69 years
31
32 (range:65-83), 121 (45%) female patients and 212 patients (79%) having gastrointestinal
33
34 cancers. For purposes of comparison, data from the seminal CARG study by Hurria et al is
35
36 provided for comparison (table 1). Details of chemotherapeutic regimens are presented in
37
38 supplementary table 1.
39
40
41

42 43 44 Chemotherapy toxicity

45
46 At least one grade 3 to 5 toxicity was seen in 140 patients (52%), with 119 (44%) having
47
48 grade 3, 22 (8%) having grade 4, and 11(4%) grade 5 toxicities. Grade 3-5 haematological
49
50 and non-haematological toxicities occurred in 60 patients (22%) and 120 (45%) patients
51
52 respectively. Common haematological toxicities were neutropenia in 26 (10%) and febrile
53
54 neutropenia in 17 (6%) patients, while common non-haematological toxicities were
55
56 infections, fatigue and diarrhoea in 54 (20%), 24 (9%) and 23 (9%) patients respectively
57
58 (table 2).
59
60

1
2
3 The incidence of grade 1 to grade 2 toxicities are listed in supplementary table 2.
4
5

6 Correlation of CARG score with toxicity and dose modifications 7 8

9 The median overall CARG risk score was 6 (range, 0 to 19). Of the 270 patients, 72 (27%),
10 164 (61%) and 34 (13%) were classified as low, intermediate and high risk, respectively
11 (table 1). Grade 3-5 toxicities were seen in 30(42%), 83 (51%) and 27 (79%) patients with
12 low, intermediate and high-risk score. There was a significant difference in toxicity amongst
13 the risk groups ($p<0.001$) (figure 1 and table 2). The odds of a patient classified as
14 intermediate risk having a grade 3-5 toxicity as compared to patient with low risk was 1.64
15 (95% CI: 1.23-2.13), while the odds of a patient classified as high risk having a grade 3-5
16 toxicity as compared to patient with low risk was 7.58 (95% CI:2.61-21.73). Area under the
17 ROC curve for the predictive model in the current cohort was 0.63 (95% CI: 0.57-0.7). The
18 correlation of individual components of the CARG risk score with grade 3-5 toxicities is
19 enumerated in supplementary table 3.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34
35 Grade 1-2 toxicities were seen in 61(86%), 144(88%) and 29 (85%) patients with low,
36 intermediate and high-risk score. There was no significant difference in toxicity amongst the
37 CARG risk groups ($p=0.79$).
38
39
40
41
42

43 The incidence of grade 2 peripheral neuropathy and grade 2 hand-foot-syndrome (HFS) are
44 separately reported as these are specifically associated with diminished function. The
45 incidence of grade 2 neuropathy was seen in 5 (7%), 11 (7%) and 2 (6%) patients in the low,
46 intermediate and high-risk categories, respectively. There was no significant difference in
47 grade 2 neuropathy amongst the CARG risk groups ($p=0.97$). The incidence of grade 2 HFS
48 was seen in 5 (7%), 18 (11%) and 2 (6%) patients in the low, intermediate and high-risk
49 categories, respectively. There was no significant difference in grade 2 HFS amongst the
50 CARG risk groups ($p=0.47$)
51
52
53
54
55
56
57
58
59
60

1
2
3 Upfront dose modifications in chemotherapy regimens were performed in 65 patients (24%).
4
5 Subsequent dose reductions were made in 89 patients (33%). On further analysis, these
6
7 subsequent dose modifications were made in 18 (25%), 59 (36%) and 12 (35%) patients in
8
9 the low, intermediate and high-risk categories, respectively. The differences in proportion of
10
11 dose modifications were not statistically significant between the 3 groups ($p=0.244$).
12
13
14

15 Association of grade 3-5 toxicity with Age adjusted Charlson 16 Comorbidity Index (ACCI) and ECOG PS 17 18

19
20 The median ACCI was 5. A $CCI \leq 4$ was seen in 111 patients (41%), while 159 patients
21
22 (59%) had a $CCI > 4$. There was no significant difference in toxicities amongst both groups
23
24 of patients ($p=0.7$) (figure 1 and table 3). The ROC of the model with CCI (as a continuous
25
26 variable) was 0.48 (95% CI: 0.41-0.55), which was lower than the ROC of the CARG risk
27
28 score model, 0.63.
29
30

31
32 ECOG PS was 0, 1 and 2 in 9(3%), 221(82%) and 40 (15%) patients, respectively. There was
33
34 no significant difference in toxicities amongst both groups of patients ($p=0.69$) (figure 1 and
35
36 table 3). The ROC of the model with ECOG PS (as a continuous variable) was 0.52 (95% CI:
37
38 0.45-0.59), which was lower than the ROC of the CARG risk score model, 0.63.
39
40
41

42 Discussion 43 44 45 46

47 This study validates the CARG risk score in older Indian patients receiving curative-intent
48
49 chemotherapy for stage I-III gastrointestinal, breast and gynecological cancers, though the
50
51 association between rates of severe chemotherapy toxicity and CARG risk groups as being
52
53 discriminatory was modest (AU-ROC 0.63). No association was found between ECOG PS
54
55 and burden of comorbidities as measured by the ACCI with severe chemotherapy related
56
57 toxicities.
58
59
60

1
2
3 There is a significant knowledge gap in terms of how older patients in general and older
4 patients with cancer fare in the Indian scenario. Limited data suggests no defined care
5 structure for older patients with cancer in India as well as only low-moderate awareness and
6 use of geriatric assessment in older patients with cancer (3,12) . Available evidence from
7 India suggests that 98% of older adult cancer patients have vulnerabilities in at least one
8 geriatric domain, though the specific vulnerabilities appear to differ from previously
9 published data (13). Such a high and differential vulnerability profile in these patients
10 suggests that they may have a different incidence of toxicities with standard chemotherapy
11 regimens. With such a background, it was essential to evaluate the validity of the CARG risk
12 score before routine advocacy in older adult patients.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 There are some important differences between the populations of the current study and the
28 seminal CARG study. The current study had only patients with stage I-III disease, while the
29 CARG study had 38% with non-metastatic disease. Other relevant differences between the
30 cohorts include a younger mean age (69 vs. 73 years), lesser comorbidities (46% with no
31 comorbidities vs. 10% with no comorbidities), and better performance on a number of
32 individual variables in the CARG risk score (better hearing, lesser number of falls, better
33 social activity and effort tolerance). There were also a lower proportion of patients with high-
34 risk score in the current study (13% vs. 22%). These differences, coupled with lack of
35 patients with metastatic disease in the study cohort, indicate that patients in the current study
36 were a well preserved and presumably fitter group of patients with lesser disease burden and
37 potential for toxicities.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 Despite the differences in patient cohorts in terms of baseline characteristics, the current
54 study validated the Cancer Aging Research Group (CARG) risk score in predicting grade 3 to
55 grade 5 chemotherapy related toxicities. The low, intermediate and high risk CARG groups
56 predicted for increasing incidences of grade 3-5 toxicities with statistical significance. The
57
58
59
60

1
2
3 odds ratios between individual risk groups for predicting grade 3-5 toxicity was also
4
5 statistically significant, highlighting the differential capability of the risk score. An
6
7 unanswered component of the CARG risk assessment was whether it correlated with grade 1-
8
9 2 toxicities. Previous studies by Moth et al estimating grade 1 and grade 2 toxicities as
10
11 toxicity burden have not shown a correlation with the CARG risk score (14). This is possibly
12
13 due to the near universal occurrence of such toxicities in patients receiving chemotherapy. A
14
15 similar trend was seen in the current study wherein an increasing risk score did not predict for
16
17 an increased risk of grade 1-2 toxicities. Additionally, in comparison to the predictive
18
19 capacity of the CARG risk score, the Charlson Comorbidity Index and ECOG PS based risk
20
21 groups did not predict for incidences of toxicity in the study. These results highlight certain
22
23 salient points in the study, Firstly, the CARG risk score can be used with confidence in the
24
25 Indian population to predict for grade 3-5 toxicity. The CARG risk score was evaluated only
26
27 in a North American elderly adult cohort initially and the current study provides validation
28
29 for the score in the Indian context. Secondly, despite being a better-preserved cohort in
30
31 comparison to the population in the seminal study as well as having only patients on curative
32
33 intent therapy, a high proportion of patients across risk groups developed grade 3-5 toxicity
34
35 which may be life-threatening. Thus, it is imperative to carefully assess the trade-off between
36
37 objectives such as survival and downstaging versus potentially life-threatening toxicities
38
39 while planning curative intent chemotherapy in older adult patients. Thirdly, the area under
40
41 the ROC for the current study was 0.63 and is lower in comparison to the original study
42
43 (0.72), though very similar to the results of the validation study (0.65) by the CARG group
44
45 (8). Though this indicates a modest discriminatory capability for the CARG risk score in the
46
47 current study, it is probably also reflective of the true value of the score in prediction of
48
49 severe chemotherapy related toxicities. Smaller studies by Australian investigators have also
50
51 previously commented on this lack of discriminatory value with the CARG risk score (14).
52
53
54
55
56
57
58
59
60

1
2
3 Finally, using a global assessment score such as ECOG PS or only one aspect of an
4 assessment profile such as comorbidity status (as in the case of ACCI) would not accurately
5 capture the heterogeneity of the older adult population. This is reflected in the inadequacy of
6 ECOG PS and ACCI in predicting for toxicities and hence, these indices should only be used
7 in conjunction with other indices as measures of assessment in older adults with cancer
8 (15,16).
9
10
11
12
13
14
15
16

17 We also attempted to correlate the CARG risk scores with the necessity for further dose
18 reductions during chemotherapy. There were no statistically significant differences between
19 the risk groups in terms of requirement for subsequent dose modifications post initiation of
20 therapy. This can partially be explained by the fact that a high proportion of patients (24%)
21 underwent initial dose reductions when planned for therapy by the treating physicians who
22 were blinded to the CARG risk score. Such an upfront dose reduction may have masked any
23 possible correlation between the risk scores and need for dose modifications during
24 chemotherapy.
25
26
27
28
29
30
31
32
33
34
35

36 Certain strengths of the current study need to be highlighted. The prospective collection of
37 toxicity data removes any recall bias that may lead to underestimation of the same. The
38 assessment in patients undergoing curative intent treatment only is novel and lays stress on
39 the conundrum faced by oncologists when balancing risks and benefits of using potentially
40 aggressive chemotherapy regimens in the neoadjuvant or adjuvant setting. The results will
41 allow patients and oncologists to discuss options with evidentiary basis for expected toxicities
42 when treatment regimens are considered. By validating the CARG risk score in an Indian
43 population, the study provides further evidence for the use of the score across geographical
44 regions.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 There are certain limitations to this study. This is a single centre study and the results may not
4 be generalizable to practice across India. There is an under-representation of non-
5 gastrointestinal cancers and this may hamper the generalization of the study results to all
6
7 solid tumors. Additionally, other common solid tumors like lung cancers, head and neck
8
9 cancers and genitourinary cancers have not been evaluated in this study. The rate of grade 3-5
10
11 toxicities was much higher than planned as per baseline statistical considerations – this may
12
13 relate to the preponderance of GI cancers in the study population, besides other differences in
14
15 baseline characteristics of the patient cohorts as has been previously discussed. Additionally,
16
17 while information with regard to correlation of the CARG risk score with grade 1-2 toxicities
18
19 has been provided, the relevance of this is limited due to the fact that almost all patients on
20
21 systemic therapy develop some grade 1 or 2 toxicity. Again, the CARG score was developed
22
23 to predict for grade 3-5 toxicities, not grade 1-2 toxicities and thus, the inability to
24
25 differentially predict for Grade 1-2 in the current study is not surprising . We also do not
26
27 have information on patient related outcomes in the study.
28
29
30
31
32
33

34
35
36 Going forward, future directions with regard to the CARG risk assessment include
37
38 developing paradigms for the degree of dose modifications required in patients based on the
39
40 score. Patients preferences with regard to tumor related endpoints versus toxicity limiting
41
42 QOL based on toxicity risk assessment can be explored in trials, especially in the advanced
43
44 cancer setting. Non-chemotherapeutic systemic treatment options like targeted therapy and
45
46 immunotherapy can be assessed by the risk score for predicting toxicity. Based on the current
47
48 study, we plan to use the CARG score routinely in our hospital as well plan prospective
49
50 studies utilizing the score to estimate dose modifications in relation to risk assessment by the
51
52 score.
53
54
55

56
57 In conclusion, the current study validates the CARG risk score in predicting for grade 3-5
58
59 toxicities in Indian older adult cancer patients receiving curative intent chemotherapy. The
60

score contributes to informed clinical decision making with regard to planning treatment and expectation of toxicity in this cohort of patients. Additionally, indices such as ECOG PS and Charlson Comorbidity Index are inadequate to predict for toxicities and should only be used along with other measures to predict for chemotherapy related toxicities.

References :

1. Marosi C, Köller M. Challenge of cancer in the elderly. *ESMO Open*. 2016 Apr 1;1(3): e000020.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin*. 2010 Oct;60(5):277–300.
3. Patil VM, Chakraborty S, Dessai S, Kumar SS, Ratheesan K, Bindu T, et al. Patterns of care in geriatric cancer patients – An audit from a rural based hospital cancer registry in Kerala. *Indian J Cancer*. 2015 Jan 1;52(1):157.
4. Zhao L, Leung L-H, Wang J, Li H, Che J, Liu L, et al. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. *BMC Pulm Med* [Internet]. 2017 Aug 15 [cited 2020 Jun 17];17. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556668/>
5. Edahyr B, Lind M, Karsera L, Mafi R, Wallace K, Howell G, et al. PUB068 The Applicability of Comorbidity Indices in Predicting Chemo toxicity in Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2017 Jan 1;12(1): S1487–8.
6. van Abbema DL, van den Akker M, Janssen-Heijnen ML, van den Berkmortel F, Hoeben A, de Vos-Geelen J, et al. Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review. *J Geriatr Oncol*. 2019 Jan 1;10(1):31–41.

- 1
2
3 7. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11. Yang C-C, Fong Y, Lin L-C, Que J, Ting W-C, Chang C-L, et al. The age-adjusted
Charlson comorbidity index is a better predictor of survival in operated lung cancer patients
than the Charlson and Elixhauser comorbidity indices. *Eur J Cardiothorac Surg*. 2018 Jan
1;53(1):235–40.
12. Noronha V, Talreja V, Joshi A, Patil V, Prabhash K. Survey for geriatric assessment
in practicing oncologists in India. *Cancer Res Stat Treat*. 2019 Jul 1;2(2):232.
13. Noronha V, Ramaswamy A, Dhekle R, Talreja V, Gota V, Gawit K, et al. Initial
experience of a geriatric oncology clinic in a tertiary cancer center in India. *Cancer Res Stat
Treat*. 2020 Jul 1;3(2):208.
14. Moth EB, Kiely BE, Stefanic N, Naganathan V, Martin A, Grimison P, et al.
Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the

CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. *J Geriatr Oncol.* 2019;10(2):202–9.

15. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. *Cancer.* 2012;118(13):3377–86.

16. Zhang J, Liao X, Feng J, Yin T, Liang Y. Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology. *Oncol Lett.* 2019 Oct 31;18(5):4947–55.

Figure legends:

Figure 1- CARG (A) vs. (B) ACCI vs. (C) ECOG PS predict Grade 3 to 5 toxicity

Tables

Table 1 - Baseline characteristics of patients

Characteristic	Current study Number (%) (n=270)	CARG training cohort (n=500)
Mean age in years (range)	69 (65-83)	73 (65-91)
Gender		
• Female	121 (45)	281 (56)
• Male	149 (55)	219 (44)

Comorbidities		
<ul style="list-style-type: none"> Hypertension Diabetes mellitus Coronary artery disease Chronic kidney disease 	<p>114 (42)</p> <p>71 (26)</p> <p>12 (4)</p> <p>3 (1)</p>	<p>52%</p> <p>-</p> <p>20%</p> <p>-</p>
Number of comorbidities		
<ul style="list-style-type: none"> 0 1 >=2 	<p>125 (46)</p> <p>95 (35)</p> <p>50 (19)</p>	<p>10%</p> <p>-</p> <p>-</p>
Cancer stage		
<ul style="list-style-type: none"> Stage I-III 	270 (100)	191 (38)
Undergone resection	210 (78)	-
ECOG performance status (clinician assessed)		
<ul style="list-style-type: none"> 0/1 2 	<p>230 (85)</p> <p>40 (15)</p>	<p>402 (80) *</p> <p>86 (17) **</p>
Factors assessed in CARG		
<ul style="list-style-type: none"> Age \geq 72 years Cancer type GI or GU Chemotherapy dosing, standard dose No. of chemotherapy drugs, polychemotherapy Hemoglobin < 11 g/dL (male), < 10 g/dL (female) Creatinine clearance < 34 mL/min Hearing, fair or worse No. of falls in last 6 months, 1 or more IADL: Taking medications, with some help/unable MOS: Walking 1 block, somewhat limited/limited a lot MOS: Decreased social activity because of physical/emotional health, limited at least sometimes 	<p>60 (22)</p> <p>212 (79)</p> <p>205 (76)</p> <p>194 (72)</p> <p>99 (37)</p> <p>5 (2)</p> <p>19 (7)</p> <p>18 (7)</p> <p>29 (11)</p> <p>17 (6)</p> <p>18 (7)</p>	<p>270 (54)</p> <p>185 (37)</p> <p>380 (76)</p> <p>351 (70)</p> <p>62 (12)</p> <p>44 (9)</p> <p>123 (25)</p> <p>91 (18)</p> <p>39 (8)</p> <p>109 (22)</p> <p>218 (44)</p>
Median overall risk score	6	7
Risk stratification		
<ul style="list-style-type: none"> Low risk (0-5 points) Intermediate risk (6-9 points) High risk (10-19 points) 	<p>72 (27)</p> <p>164 (61)</p> <p>34 (13)</p>	<p>128 (26)</p> <p>227 (45)</p> <p>109 (22)</p>
Age adjusted Charlson's Comorbidity Index		
<ul style="list-style-type: none"> \leq4 >4 	<p>111(41)</p> <p>159(59)</p>	<p>-</p> <p>-</p>

*equivalent to KPS \geq 80; ** equivalent to KPS 60-70

Table 2 – Treatment related Grade 3 – grade 5 toxicities

Toxicity type	Grade 3 (%)	Grade 4 (%)	Grade 5 (%)
Haematological			
Anemia	14 (5)	0	0
Neutropenia	18 (7)	8(3)	0
Thrombocytopenia	6 (2)	1 (0.4)	0
Febrile neutropenia	12 (4)	2 (0.7)	3(1)
Cumulative haematological	46 (17)	11 (4)	3(1)
Non-haematological			
Diarrhoea	16 (6)	4 (2)	3(1) *
Vomiting	12 (4)	1(0.4)	1(0.3) **
Mucositis	10 (4)	0	
Constipation	1 (0.4)	0	
Hand-foot-syndrome	1 (0.4)	-	

Neuropathy	3 (1)	-	
Infection with normal ANC	47 (17)	7(3)	
Hyponatremia	8 (3)	2 (0.7)	
Fatigue	24 (9)	-	
Sudden cardiac death			4(1)
Cumulative non-haematological	99(37)	13(5)	8(3)
Cumulative (all toxicities)	119(44)	22(8)	11(4)

*All 3 patients developed dehydration with resulting acute renal failure. **Patient developed grade 4 vomiting with irreversible grade 4 hyponatremia resulting in death


Table 3 - Ability of CARG Risk Score Versus Physician assessed ECOG PS Versus Age adjusted Charlson's Comorbidity Index (ACCI) to Predict Grade 3-5 Chemotherapy Toxicity

Risk Stratification	No toxicity		Toxicity		p value
	Number	%	Number	%	
CARG risk score					0.001
• Low	42	58	30	42	
• Intermediate	81	49	83	51	
• High	7	21	27	79	
Physician assessed ECOG PS					0.69
• 0	5	56	4	44	
• 1	108	49	113	51	
• 2	17	43	23	57	

Age adjusted Charlson's Comorbidity Index					
• ≤4	55	50	56	50	0.7
• >4	75	47	84	53	

For peer review only

Figure 1 – Ability of CARG risk score (A) versus (B) Age adjusted Charlson Comorbidity Index (ACCI) versus (C) ECOG Performance Status Index to predict Grade 3 to 5 chemotherapy toxicity.



Supplementary table 1 – Details of chemotherapy

Chemotherapy regimens	Number (percentage)
Platinum containing regimens	159(59)
Oxaliplatin containing regimens	123 (46)
• Docetaxel-Oxaliplatin- 5 -fluorouracil	50 (19)
• Capecitabine-Oxaliplatin	26 (10)
• 5-fluorouracil - leucovorin-oxaliplatin	33 (12)
• 5-fluorouracil - leucovorin-oxaliplatin-irinotecan	1 (0.4)
• Epirubicin- Capecitabine-Oxaliplatin	10 (4)
• Gemcitabine-Oxaliplatin	2 (1)
• Epirubicin- Oxaliplatin - 5-fluorouracil	1 (0.4)
Cisplatin containing regimens	19(7)
• Gemcitabine-Cisplatin	19 (7)
Carboplatin containing regimens	17 (6)
• Paclitaxel- Carboplatin	6 (2)
• Carboplatin monotherapy	11 (4)
Non-Platinum containing regimens	111(41)
• Epirubicin – Cyclophosphamide	9 (3)
• Adriamycin – Cyclophosphamide	19 (7)
• Docetaxel – Cyclophosphamide	1 (0.4)
• Cyclophosphamide-methotrexate – 5-fluorouracil	1 (0.4)
• 5-fluorouracil/leucovorin monotherapy	10 (4)
• Capecitabine monotherapy	25 (9)
• Gemcitabine monotherapy	26 (10)
• Paclitaxel - Trastuzumab	9 (3)
• Paclitaxel monotherapy	3 (1)
• Docetaxel - 5-fluorouracil	5 (2)
• Gemcitabine- nab-Paclitaxel	2 (1)
• Gemcitabine Capecitabine	1 (0.4)
Chemotherapy timing	
• Neoadjuvant	5 (2)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

• Adjuvant	178 (66)
• Perioperative (neoadjuvant and adjuvant)	87 (32)

Supplementary table 2 – Treatment- related Grade 1 – grade 2 toxicities

Toxicity type	Grade 1/2 toxicities (%)
Hematological	
Anemia	148(55)
Neutropenia	52(19)
Cumulative hematological	160(59)
Non-hematological	
Diarrhoea	131(49)
Vomiting	140(52)
Mucositis	57(21)
Constipation	41(15)
Hand-foot-syndrome	59(22)
Neuropathy	75(28)
Hyponatremia	17(6)
Fatigue	197(73)
Cumulative non-hematological	230(85)
Cumulative (all toxicities)	234(87)

Supplementary table 3 - Ability of individual factors in the CARG risk score to predict for Grade 3 to 5 toxicities

Risk factor	Prevalence		Toxicity		p value	OR (95% CI)
	Number	%	Number	%		
Age \geq 72 years	60	22	34	57	0.4	1.28 (0.72-2.29)
Cancer type (GI or GU)	212	79	116	55	0.07	1.71 (0.95-3.08)
Chemotherapy dosing, standard dose	201	74	101	50	0.37	0.77 (0.45-1.35)
Polychemotherapy	194	72	106	55	0.14	1.48 (0.87-2.54)
Hemoglobin $<$ 11 gm% (male), $<$ 10 gm% (female)	99	37	65	66	0.001	2.45(1.47-4.09)
Creatinine clearance $<$ 34ml/min	5	2	3	60	0.71	1.4(0.23-8.52)
Hearing, fair or worse	19	7	10	53	0.94	1.03(0.41-2.63)
No. of falls in last 6 months, \geq 1	18	7	10	56	0.75	1.17(0.45-3.07)
IADL, taking medications, with some help/unable	29	11	17	59	0.44	1.336 (0.62-2.97)
MOS, walking 1 block equivalent, somewhat limited/limited a lot	17	6	11	65	0.27	1.76 (0.63-4.91)
MOS, decreased social activity because of physical/emotional health, limited at least sometimes	18	7	12	67	0.19	1.94(0.71-5.32)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	6
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	9
Objectives	3	State specific objectives, including any prespecified hypotheses	10
Methods			
Study design	4	Present key elements of study design early in the paper	10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	10
		(b) For matched studies, give matching criteria and number of exposed and unexposed	10
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11
Bias	9	Describe any efforts to address potential sources of bias	12
Study size	10	Explain how the study size was arrived at	12
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	12
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	12
		(b) Describe any methods used to examine subgroups and interactions	12
		(c) Explain how missing data were addressed	12
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			13

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	13
		(b) Give reasons for non-participation at each stage	13
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13
		(b) Indicate number of participants with missing data for each variable of interest	13
		(c) Summarise follow-up time (eg, average and total amount)	13
Outcome data	15*	Report numbers of outcome events or summary measures over time	14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14
Discussion			
Key results	18	Summarise key results with reference to study objectives	15
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	5

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Cancer Ageing Research Group (CARG) score in older adults undergoing curative intent chemotherapy: A prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-047376.R2
Article Type:	Original research
Date Submitted by the Author:	18-May-2021
Complete List of Authors:	Ostwal, Vikas; Tata Memorial Centre, Medical Oncology Ramaswamy, Anant; Tata Memorial Centre, Department of medical Oncology Bhargava, Prabhat; Tata Memorial Centre Hatkambkar, Tejaswee; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Swami, Rohit; Narayana Multi speciality Hospital, Jaipur India. , Medical Oncology Rastogi, Sameer; AIIMS New Delhi, India. Mandavkar, Sarika; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Ghosh, Jaya; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Bajpai, Jyoti; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Gulia, Seema; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Srinivas, Sujay; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology Rath, Sushmita; Tata Memorial Centre Gupta, Sudeep; Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of medical Oncology
Primary Subject Heading:	Geriatric medicine
Secondary Subject Heading:	Oncology, Pharmacology and therapeutics, Medical management, Geriatric medicine, Health services research
Keywords:	CHEMOTHERAPY, Adult oncology < ONCOLOGY, Gynaecological oncology < ONCOLOGY, Gastrointestinal tumours < ONCOLOGY, Breast tumours < ONCOLOGY, Adverse events < THERAPEUTICS

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title – Cancer Ageing Research Group (CARG) score in older adults undergoing curative intent chemotherapy: A prospective cohort study

TITLE PAGE

Running title –CARG score in older Indian cancer patients undergoing curative-intent chemotherapy

Authors

1. Dr. Vikas Ostwal

Professor, Department of Medical Oncology,

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Email: dr.vikas.ostwal@gmail.com

2. Dr. Anant Ramaswamy

Associate Professor, Department of Medical Oncology,

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Email: anantr13@gmail.com

3. Dr Prabhat Bhargava

Assistant Professor, Department of Medical Oncology,

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

1
2
3 Email: bhargava611@gmail.com
4
5
6
7

8
9 4. Ms. Tejaswee Hatkhambkar

10
11 Research coordinator, Department of Medical Oncology,
12

13
14 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
15

16
17 Email: tejasweehatkhambkar@gmail.com
18
19

20
21
22 5. Dr Rohit Swami

23
24 Assistant Professor, Department of Medical Oncology,
25

26
27 Narayana Multi specialty Hospital, Jaipur India.
28

29
30 Email: swamirohit21@yahoo.in
31
32

33
34
35 6. Dr Sameer Rastogi

36
37 Associate Professor, Department of Medical Oncology,
38

39
40 AIIMS New Delhi, India.
41

42
43 Email: samdoc_mamc@yahoo.com
44
45

46
47
48 7. Ms. Sarika Mandavkar

49
50 Research nurse, Department of Medical Oncology,
51

52
53 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
54

55
56 Email: sarikamandavkar1@gmail.com
57
58
59
60

1
2
3
4
5
6 8. Dr. Jaya Ghosh
7

8
9 Professor, Department of Medical Oncology,

10
11 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
12

13
14 Email: archana_jaya_ghosh@yahoo.co.in
15
16
17
18
19

20 9. Dr. Jyoti Bajpai

21
22 Professor, Department of Medical Oncology,
23

24
25 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
26
27

28 Email: dr_jyotibajpai@yahoo.co.in
29
30
31
32
33

34 10. Dr. Seema Gulia

35
36 Professor, Department of Medical Oncology,
37

38
39 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
40
41

42 Email: drseemagulia@gmail.com
43
44
45
46
47

48 11. Dr. Sujay Srinivas

49
50 Assistant Professor, Department of Medical Oncology,
51

52
53 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
54
55

56 Email: sujay.0541@gmail.com
57
58
59
60

1
2
3 12. Dr Sushmita Rath
4

5
6 Assistant Professor, Department of Medical Oncology,
7

8
9 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
10

11
12 Email: sushmitarath73@gmail.com
13
14

15
16
17 13. Dr Sudeep Gupta
18

19
20 Professor, Department of Medical Oncology,
21

22
23 Director ACTREC, Room 309/310, 3rd Floor, Paymaster Shodhika,
24

25
26 ACTREC (Advanced Centre for Treatment, Research and Education in Cancer), Homi Bhabha
27

28
29 National Institute (HBNI), Navi Mumbai - 410210, Maharashtra, India
30

31
32 Email id - sudeepgupta04@yahoo.com
33
34

35
36 Corresponding author
37

38
39 Dr. Anant Ramaswamy
40

41
42 Associate Professor, Department of Medical Oncology,
43

44
45 Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
46

47
48 Email: anantr13@gmail.com
49
50

51
52 Funding:
53

54
55 Received grants to Tata Memorial centre, Mumbai for the conduct of present study from
56

- 57
58 a. Indian Association of Supportive Care in Cancer awarded research award during BEST OF
59
60 MASCC 2019. **Grant number: 1716-A**

- 1
2
3 b. Intas Pharmaceuticals Private Limited **Grant number: 1716-B – The Pharmaceutical**
4 **company, Intas Pharmaceutical Private Limited, provided an unrestricted educational**
5 **grant to Tata Memorial Centre (The Institute) for the conduct of the study. This was**
6 **utilized for appointing a trained medical doctor for the purpose of the study.**
7
8
9
10
11
12
13
14

15 Prior presentation: None

16
17 Conflict of interest: None

18
19 Author Contributions:

20
21
22
23 **1. Dr. Vikas Ostwal**

24
25 Author contribution - Conception and design, analysis and interpretation of data,
26
27 drafting of manuscript, Final approval of the submitted version.

28
29
30 **2. Dr. Anant Ramaswamy**

31
32 Author contribution - Conception and design, analysis and interpretation of data,
33
34 drafting of manuscript, Final approval of the submitted version.

35
36
37 **3. Dr Prabhat Bhargava**

38
39 Author contribution - analysis and interpretation of data, drafting of manuscript,
40
41 Final approval of the submitted version.
42
43
44
45
46

47
48 **4. Ms. Tejaswee Hatkhambkar**

49
50 Author contribution - analysis and interpretation of data, Final approval of the
51
52 submitted version.
53

54
55 **5. Dr Rohit Swami**

56
57 Author contribution - analysis and interpretation of data, drafting of manuscript,
58
59 Final approval of the submitted version.
60

1
2
3 6. Dr Sameer Rastogi
4

5 Author contribution - Conception and design, drafting of manuscript, Final approval
6 of the submitted version.
7
8

9
10 7. Ms. Sarika Mandavkar
11

12 Author contribution - analysis and interpretation of data, drafting of manuscript,
13 Final approval of the submitted version.
14
15

16 8. Dr. Jaya Ghosh
17

18 Author contribution - analysis and interpretation of data, drafting of manuscript,
19 Final approval of the submitted version.
20
21

22 9. Dr Sushmita Rath
23

24 Author contribution - analysis and interpretation of data, drafting of manuscript,
25 Final approval of the submitted version.
26
27

28 10. Dr. Jyoti Bajpai
29

30 Author contribution - analysis and interpretation of data, drafting of manuscript,
31 Final approval of the submitted version.
32
33

34 11. Dr. Seema Gulia
35

36 Author contribution - analysis and interpretation of data, drafting of manuscript,
37 Final approval of the submitted version.
38
39

40 12. Dr Sujay Srinivas
41

42 Author contribution - analysis and interpretation of data, drafting of manuscript,
43 Final approval of the submitted version.
44
45
46
47
48
49
50

1
2
3 13. Dr Sudeep Gupta
4

5 Author contribution - Conception and design, analysis and interpretation of data,
6
7 drafting of manuscript, Final approval of the submitted version.
8
9

10
11 Acknowledgements: Nil
12

13
14 Clinical trial registration: CTRI/2016/10/007357
15

16
17 Ethics committee Clearance:
18

- 19
20
21 1. Name of the Ethics committee: Institutional Ethics committee, Tata Memorial
22
23 Centre, Parel, Mumbai.
24
25
26
27
28 2. IEC approval ID: IEC/1019/1716/001
29
30
31
32 3. The participants gave informed consent before taking part in the study.
33
34
35

36
37 Word count: 3398 (excluding abstract and references)
38

39
40 Data Availability statement: Data are available upon reasonable request
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract:

Importance:

The Cancer Aging Research Group (CARG) toxicity score is used to assess toxicity risk in geriatric patients receiving chemotherapy.

Objective:

The primary aim was to validate the CARG score in geriatric patients treated with curative intent chemotherapy in predicting Grade 3-5 toxicities.

Design:

This was a longitudinal prospective observational study

Setting:

Tata Memorial Hospital, Mumbai, India, a tertiary cancer care referral centre.

Participants:

Patients age ≥ 65 with gastrointestinal, breast or gynaecological stage I-III cancers being planned for curative intent chemotherapy. A total of 270 patients were required for accrual in the study.

Exposure(s):

Total risk score ranged from 0 (lowest toxicity risk) to 19 (highest toxicity risk).

Main Outcome(s) and Measure(s):

The primary endpoint of the study was to evaluate whether the CARG risk score predicted for grade 3-5 toxicities.

Results:

1
2
3 The study cohort of 270 patients had a mean age of 69 years (65-83), with the most common
4 cancers being gastrointestinal (79%). Fifty-two percent of patients had at-least one grade 3-5
5 toxicity. The risk of toxicity was increased with increasing risk score (42% low, 51%
6 medium, 79% high risk; $P < .001$). There was no association between either ECOG PS
7 (p=0.69) or age adjusted Charlson Comorbidity Index (p=0.79) risk categories and grade 3-5
8 chemotherapy toxicity.
9
10
11
12
13
14
15
16

17 **Conclusions and Relevance:**

18
19
20 The current study validates the CARG risk score in predicting for grade 3-5 toxicities in
21 geriatric oncology patients receiving curative intent chemotherapy and can be considered as
22 standard of care before planning chemotherapy in every elderly patient.
23
24
25
26
27
28
29
30

31 **Key words** – CARG risk; Hurria score, curative, ECOG PS, Charlson Comorbidity Index,
32 chemotoxicity
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Strengths and limitations of the study:**
4

- 5
- 6 • The CARG risk score is a simple tool comprising easily available clinical information.
 - 7
 - 8 • This is a prospective study to assess CARG risk score in elderly patients treated with
9
10 curative intent to predict for grade 3-5 toxicities.
 - 11
 - 12 • CARG score performed better than traditional indices such as the age adjusted Charlson
13
14 Comorbidity Index and ECOG PS.
 - 15
 - 16 • The results suggest that the CARG score is valid in the studied population and can be
17
18 routinely used in clinical practice.
 - 19
 - 20 • This study does not include palliative patients and mainly GI cancer patients were
21
22 recruited.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 **Manuscript:**
59
60

Introduction

Older adult patients (age ≥ 65 years) with cancer represent a growing proportion of patients in community clinical practice, primarily due to increasing life-spans as well as medical progress contributing to decreased morbidity and mortality from other causes (1). Elderly patients comprise anywhere between 20% to 60% in community oncology practice, with variances based on access to cancer care, disease stage and centre specific management strategies (2,3).

The age adjusted Charlson Comorbidity Index (ACCI) and ECOG Performance status (PS) amongst others have often been used to quantify risks and predict for outcomes in older adults with cancer, but there is limited data for correlation between these indices and treatment related side effects (4–6). The Cancer Aging Research Group (CARG) risk score, developed by Hurria and colleagues, is an easy-to-use tool that predicts for significant chemotherapy related toxicities (grade 3- grade 5) in older North American adults ≥ 65 years starting on chemotherapy (7,8). Based on their training samples and subsequent validation studies, the investigators clearly identified low, mid and high-risk groups predicting for increasing rates of grade 3-5 toxicities (low risk: 30%, intermediate risk: 52%, high risk: 83%) with statistical significance ($P < 0.001$). The CARG risk score has been validated in other countries and in specific tumor sites to varying degrees (9,10).

In older adults being treated with curative intent chemotherapy, there is the possibility of treating oncologists using standard doses to maximize outcomes, despite patient related indicators suggesting a requirement for lower doses. This is a unique scenario where further information on risks and benefits would allow for informed clinical decision making on doses and drugs to be used. As patients with all stages of cancer were included in the CARG studies, the ambiguity with regard to its usage in patients being treated with potentially curative intent lends itself to re-examination.

1
2
3 With this background, the investigators conducted a longitudinal prospective study with the
4 primary aim of validating the CARG risk score in Indian older cancer patients treated with
5 curative intent chemotherapy (neoadjuvant or/and adjuvant chemotherapy). Secondary and
6 objectives included correlation of the age adjusted Charlson Comorbidity Index (ACCI) and
7 physician measured ECOG PS with grade 3-5 toxicities. An exploratory component of the
8 study involved an estimation of grade 1 and grade 2 toxicities and their correlation with the
9 CARG risk score.
10
11
12
13
14
15
16
17
18
19

20 **Materials and methods**

21 **Patient selection and design**

22
23
24 The study was designed as a longitudinal prospective observational study to validate the
25 CARG risk score in predicting chemotherapy toxicity risk in elderly patients. The study was
26 conducted at the Tata Memorial Hospital and enrolled consecutive patients aged ≥ 65 years,
27 chemotherapy naïve, with a histological diagnosis of gastrointestinal, breast or gynecological
28 cancer, stage I-III disease and planned for neoadjuvant or adjuvant systemic chemotherapy as
29 a potentially curative treatment option.
30
31
32
33
34
35
36
37
38
39

40
41 The study was designed by investigators from the Department of Medical Oncology of the Tata
42 Memorial Hospital and was approved by the ethics committee (IEC/1019/1716/001). The study
43 was registered at Clinical trial registry of India (CTRI/2016/10/007357). Written informed
44 consent was obtained from all patients before inclusion in the study.
45
46
47
48
49

50 **Patient and public involvement:**

51
52 There was no public or patient involvement in design, conduct or results declaration of the
53 study.
54
55
56
57
58
59
60

Study procedures

Data regarding tumor type and stage, pre-treatment laboratory values, and chemotherapy regimen were recorded. All patients underwent standard pre-chemotherapy work up, including evaluation of end organ function. Patients were planned for chemotherapy by treating oncologist (with an assessment of ECOG PS and ACCI), who was blinded to the risk score. A trained medical doctor calculated the CARG risk score for patients enrolled in the study. The assessment of the score by the trained medical doctor was independently reviewed by an oncologist who was not part of the treating team (7). Total risk score ranged from 0 (lowest toxicity risk) to 19 (highest toxicity risk), with division of the scores into low risk (0-5 points), intermediate risk (6 to 9 points) and high risk (10-19 points) as per the classification in the original study by Hurria et al (7). One modification of the original CARG risk score which was used in the current study was the measurement of 'Walking 1 block'. The concept of measuring distances by a block is not prevalent in India and hence, a distance of 100 meters in the immediate vicinity of the hospital was measured and patients were scored on their ability to walk the same. The chemotherapy dosing for the first cycle of chemotherapy was categorized as 'standard' if 100% doses were planned and 'dose reduced' if any dose below 100% was used. The decision for dose modifications, whether initial or subsequent, was based on assessment by treating oncologist. Besides CARG risk score, the age adjusted Charlson's Comorbidity Index (ACCI) was calculated for all patients as part of standard assessment of older adults with cancer. A cut-off of 4 points (≤ 4 and >4) was used to differentiate between low and high CCI scores (11). Patients were followed from beginning till the end of chemotherapy course across all cycles of therapy, though occurrence of a single grade 3-4 toxicity was considered as an endpoint for the purpose of toxicity calculation in the study. Toxicities were captured prospectively at all clinical visits (by treating oncologist and trained medical doctor) and graded as per National Cancer Institute

1
2
3 Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. Decision on
4 relatedness of toxicity to chemotherapy was made by treating physician. Laboratory values
5 were captured as grade 1 to 5 toxicity if they met the criteria on the date of scheduled
6 chemotherapy or when patient was seeking attention because of treatment related toxicities.
7
8
9
10
11
12

13 Outcomes

14
15
16 The primary outcome of the study was the occurrence of any grade 3-5 chemotherapy related
17 toxicity over the course of planned treatment and its association with the CARG risk score.
18
19 The planned secondary endpoints of the study were the correlation of ACCI and ECOG PS
20 with grade 3-5 chemotherapy related toxicity. Occurrence of any grade 1-2 chemotherapy
21 related toxicity and its correlation with CARG risk score was an exploratory aspect of the
22 study.
23
24
25
26
27
28
29
30

31 Statistical analysis

32
33
34
35 Descriptive analyses were performed to enumerate patient, tumor, treatment characteristics,
36 CARG risk scores and ACCI. The incidence of grade 3 to grade 5 toxicities were calculated
37 and compared between CARG risk groups, and ECOG PS cohorts by using the chi-square
38 test. The CARG risk score is not routinely used in clinical practice in our institution and we
39 did not have baseline data for the same for the purpose of sample size calculation . We
40 conducted an internal audit of elderly patients with breast, gastrointestinal and gynecological
41 cancers receiving curative intent chemotherapy in our hospital and found a 20 % incidence
42 of grade 3-grade 5 toxicities in elderly patients with ECOG PS 0/1 and controlled or absent
43 comorbidities (surrogate for “low risk) as opposed to 36% in elderly patients with ECOG PS
44 2 with or without multiple uncontrolled comorbidities (surrogate for “ high risk”).
45
46
47
48
49
50
51
52
53
54
55
56
57
58 Extrapolating these results, a power of 80% and alpha of 5% with 1 sided assumption was
59
60

1
2
3 required with an estimated sample size required being 246 patients. Assuming an attrition rate
4
5 of 10%, a total of 270 patients were required for enrolment in the study. Chi square test was
6
7 performed to test the association of the CARG risk score, PS, and ACCI with G 3-5 toxicities
8
9 and for association of CARG risk score with grade 1-2 toxicities as well dose modifications.
10
11 The predictive ability of the CARG risk score was evaluated by calculating receiver-
12
13 operating characteristic (ROC) curves and calculating the area under the curve (also known
14
15 as C-statistic). ROC curves were also calculated for ECOG PS and ACCI. All analyses were
16
17 performed using SPSS version 25. All tests were two-sided, and a P value of <0.05 was
18
19 considered statistically significant.
20
21
22
23

24 25 Results

26 27 28 Patient and treatment characteristics

29
30 The study completed accrual of 270 patients, with mean age of patients being 69 years
31
32 (range:65-83), 121 (45%) female patients and 212 patients (79%) having gastrointestinal
33
34 cancers. For purposes of comparison, data from the seminal CARG study by Hurria et al is
35
36 provided for comparison (table 1). Details of chemotherapeutic regimens are presented in
37
38 supplementary table 1.
39
40
41

42 43 Chemotherapy toxicity

44
45 At least one grade 3 to 5 toxicity was seen in 140 patients (52%), with 119 (44%) having
46
47 grade 3, 22 (8%) having grade 4, and 11(4%) grade 5 toxicities. Grade 3-5 haematological
48
49 and non-haematological toxicities occurred in 60 patients (22%) and 120 (45%) patients
50
51 respectively. Common haematological toxicities were neutropenia in 26 (10%) and febrile
52
53 neutropenia in 17 (6%) patients, while common non-haematological toxicities were
54
55 infections, fatigue and diarrhoea in 54 (20%), 24 (9%) and 23 (9%) patients respectively
56
57 (table 2).
58
59
60

1
2
3 The incidence of grade 1 to grade 2 toxicities are listed in supplementary table 2.
4
5

6 Correlation of CARG score with toxicity and dose modifications 7 8

9 The median overall CARG risk score was 6 (range, 0 to 19). Of the 270 patients, 72 (27%),
10 164 (61%) and 34 (13%) were classified as low, intermediate and high risk, respectively
11 (table 1). Grade 3-5 toxicities were seen in 30(42%), 83 (51%) and 27 (79%) patients with
12 low, intermediate and high-risk score. There was a significant difference in toxicity amongst
13 the risk groups ($p<0.001$) (figure 1 and table 2). The odds of a patient classified as
14 intermediate risk having a grade 3-5 toxicity as compared to patient with low risk was 1.64
15 (95% CI: 1.23-2.13), while the odds of a patient classified as high risk having a grade 3-5
16 toxicity as compared to patient with low risk was 7.58 (95% CI:2.61-21.73). Area under the
17 ROC curve for the predictive model in the current cohort was 0.63 (95% CI: 0.57-0.7). The
18 correlation of individual components of the CARG risk score with grade 3-5 toxicities is
19 enumerated in supplementary table 3.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34
35 Grade 1-2 toxicities were seen in 61(86%), 144(88%) and 29 (85%) patients with low,
36 intermediate and high-risk score. There was no significant difference in toxicity amongst the
37 CARG risk groups ($p=0.79$).
38
39
40
41
42

43 The incidence of grade 2 peripheral neuropathy and grade 2 hand-foot-syndrome (HFS) are
44 separately reported as these are specifically associated with diminished function. The
45 incidence of grade 2 neuropathy was seen in 5 (7%), 11 (7%) and 2 (6%) patients in the low,
46 intermediate and high-risk categories, respectively. There was no significant difference in
47 grade 2 neuropathy amongst the CARG risk groups ($p=0.97$). The incidence of grade 2 HFS
48 was seen in 5 (7%), 18 (11%) and 2 (6%) patients in the low, intermediate and high-risk
49 categories, respectively. There was no significant difference in grade 2 HFS amongst the
50 CARG risk groups ($p=0.47$)
51
52
53
54
55
56
57
58
59
60

1
2
3 Upfront dose modifications in chemotherapy regimens were performed in 65 patients (24%).
4
5 Subsequent dose reductions were made in 89 patients (33%). On further analysis, these
6
7 subsequent dose modifications were made in 18 (25%), 59 (36%) and 12 (35%) patients in
8
9 the low, intermediate and high-risk categories, respectively. The differences in proportion of
10
11 dose modifications were not statistically significant between the 3 groups ($p=0.244$).
12
13
14

15 Association of grade 3-5 toxicity with Age adjusted Charlson 16 Comorbidity Index (ACCI) and ECOG PS 17 18

19
20 The median ACCI was 5. A $CCI \leq 4$ was seen in 111 patients (41%), while 159 patients
21
22 (59%) had a $CCI > 4$. There was no significant difference in toxicities amongst both groups
23
24 of patients ($p=0.7$) (figure 1 and table 3). The ROC of the model with CCI (as a continuous
25
26 variable) was 0.48 (95% CI: 0.41-0.55), which was lower than the ROC of the CARG risk
27
28 score model, 0.63.
29
30

31
32 ECOG PS was 0, 1 and 2 in 9(3%), 221(82%) and 40 (15%) patients, respectively. There was
33
34 no significant difference in toxicities amongst both groups of patients ($p=0.69$) (figure 1 and
35
36 table 3). The ROC of the model with ECOG PS (as a continuous variable) was 0.52 (95% CI:
37
38 0.45-0.59), which was lower than the ROC of the CARG risk score model, 0.63.
39
40
41

42 Discussion 43 44 45 46

47 This study validates the CARG risk score in older Indian patients receiving curative-intent
48
49 chemotherapy for stage I-III gastrointestinal, breast and gynecological cancers, though the
50
51 association between rates of severe chemotherapy toxicity and CARG risk groups as being
52
53 discriminatory was modest (AU-ROC 0.63). No association was found between ECOG PS
54
55 and burden of comorbidities as measured by the ACCI with severe chemotherapy related
56
57 toxicities.
58
59
60

1
2
3 There is a significant knowledge gap in terms of how older patients in general and older
4 patients with cancer fare in the Indian scenario. Limited data suggests no defined care
5 structure for older patients with cancer in India as well as only low-moderate awareness and
6 use of geriatric assessment in older patients with cancer (3,12) . Available evidence from
7 India suggests that 98% of older adult cancer patients have vulnerabilities in at least one
8 geriatric domain, though the specific vulnerabilities appear to differ from previously
9 published data (13). Such a high and differential vulnerability profile in these patients
10 suggests that they may have a different incidence of toxicities with standard chemotherapy
11 regimens. With such a background, it was essential to evaluate the validity of the CARG risk
12 score before routine advocacy in older adult patients.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 There are some important differences between the populations of the current study and the
28 seminal CARG study. The current study had only patients with stage I-III disease, while the
29 CARG study had 38% with non-metastatic disease. Other relevant differences between the
30 cohorts include a younger mean age (69 vs. 73 years), lesser comorbidities (46% with no
31 comorbidities vs. 10% with no comorbidities), and better performance on a number of
32 individual variables in the CARG risk score (better hearing, lesser number of falls, better
33 social activity and effort tolerance). There were also a lower proportion of patients with high-
34 risk score in the current study (13% vs. 22%). These differences, coupled with lack of
35 patients with metastatic disease in the study cohort, indicate that patients in the current study
36 were a well preserved and presumably fitter group of patients with lesser disease burden and
37 potential for toxicities.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 Despite the differences in patient cohorts in terms of baseline characteristics, the current
54 study validated the Cancer Aging Research Group (CARG) risk score in predicting grade 3 to
55 grade 5 chemotherapy related toxicities. The low, intermediate and high risk CARG groups
56 predicted for increasing incidences of grade 3-5 toxicities with statistical significance. The
57
58
59
60

1
2
3 odds ratios between individual risk groups for predicting grade 3-5 toxicity was also
4
5 statistically significant, highlighting the differential capability of the risk score. An
6
7 unanswered component of the CARG risk assessment was whether it correlated with grade 1-
8
9 2 toxicities. Previous studies by Moth et al estimating grade 1 and grade 2 toxicities as
10
11 toxicity burden have not shown a correlation with the CARG risk score (14). This is possibly
12
13 due to the near universal occurrence of such toxicities in patients receiving chemotherapy. A
14
15 similar trend was seen in the current study wherein an increasing risk score did not predict for
16
17 an increased risk of grade 1-2 toxicities. Additionally, in comparison to the predictive
18
19 capacity of the CARG risk score, the Charlson Comorbidity Index and ECOG PS based risk
20
21 groups did not predict for incidences of toxicity in the study. These results highlight certain
22
23 salient points in the study, Firstly, the CARG risk score can be used with confidence in the
24
25 Indian population to predict for grade 3-5 toxicity. The CARG risk score was evaluated only
26
27 in a North American elderly adult cohort initially and the current study provides validation
28
29 for the score in the Indian context. Secondly, despite being a better-preserved cohort in
30
31 comparison to the population in the seminal study as well as having only patients on curative
32
33 intent therapy, a high proportion of patients across risk groups developed grade 3-5 toxicity
34
35 which may be life-threatening. Thus, it is imperative to carefully assess the trade-off between
36
37 objectives such as survival and downstaging versus potentially life-threatening toxicities
38
39 while planning curative intent chemotherapy in older adult patients. Thirdly, the area under
40
41 the ROC for the current study was 0.63 and is lower in comparison to the original study
42
43 (0.72), though very similar to the results of the validation study (0.65) by the CARG group
44
45 (8). Though this indicates a modest discriminatory capability for the CARG risk score in the
46
47 current study, it is probably also reflective of the true value of the score in prediction of
48
49 severe chemotherapy related toxicities. Smaller studies by Australian investigators have also
50
51 previously commented on this lack of discriminatory value with the CARG risk score (14).
52
53
54
55
56
57
58
59
60

1
2
3 Finally, using a global assessment score such as ECOG PS or only one aspect of an
4 assessment profile such as comorbidity status (as in the case of ACCI) would not accurately
5 capture the heterogeneity of the older adult population. This is reflected in the inadequacy of
6 ECOG PS and ACCI in predicting for toxicities and hence, these indices should only be used
7 in conjunction with other indices as measures of assessment in older adults with cancer
8 (15,16).
9
10
11
12
13
14
15
16

17 We also attempted to correlate the CARG risk scores with the necessity for further dose
18 reductions during chemotherapy. There were no statistically significant differences between
19 the risk groups in terms of requirement for subsequent dose modifications post initiation of
20 therapy. This can partially be explained by the fact that a high proportion of patients (24%)
21 underwent initial dose reductions when planned for therapy by the treating physicians who
22 were blinded to the CARG risk score. Such an upfront dose reduction may have masked any
23 possible correlation between the risk scores and need for dose modifications during
24 chemotherapy.
25
26
27
28
29
30
31
32
33
34
35
36

37 Certain strengths of the current study need to be highlighted. The prospective collection of
38 toxicity data removes any recall bias that may lead to underestimation of the same. The
39 assessment in patients undergoing curative intent treatment only is novel and lays stress on
40 the conundrum faced by oncologists when balancing risks and benefits of using potentially
41 aggressive chemotherapy regimens in the neoadjuvant or adjuvant setting. The results will
42 allow patients and oncologists to discuss options with evidentiary basis for expected toxicities
43 when treatment regimens are considered. By validating the CARG risk score in an Indian
44 population, the study provides further evidence for the use of the score across geographical
45 regions.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 There are certain limitations to this study. This is a single centre study and the results may not
4 be generalizable to practice across India. There is an under-representation of non-
5 gastrointestinal cancers and this may hamper the generalization of the study results to all
6 solid tumors. Additionally, other common solid tumors like lung cancers, head and neck
7 cancers and genitourinary cancers have not been evaluated in this study. The rate of grade 3-5
8 toxicities was much higher than planned as per baseline statistical considerations – this may
9 relate to the preponderance of GI cancers in the study population, besides other differences in
10 baseline characteristics of the patient cohorts as has been previously discussed. Additionally,
11 while information with regard to correlation of the CARG risk score with grade 1-2 toxicities
12 has been provided, the relevance of this is limited due to the fact that almost all patients on
13 systemic therapy develop some grade 1 or 2 toxicity. Again, the CARG score was developed
14 to predict for grade 3-5 toxicities, not grade 1-2 toxicities and thus, the inability to
15 differentially predict for Grade 1-2 in the current study is not surprising . We also do not
16 have information on patient related outcomes in the study.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Going forward, future directions with regard to the CARG risk assessment include developing paradigms for the degree of dose modifications required in patients based on the score. Patients preferences with regard to tumor related endpoints versus toxicity limiting QOL based on toxicity risk assessment can be explored in trials, especially in the advanced cancer setting. Non-chemotherapeutic systemic treatment options like targeted therapy and immunotherapy can be assessed by the risk score for predicting toxicity. Based on the current study, we plan to use the CARG score routinely in our hospital as well plan prospective studies utilizing the score to estimate dose modifications in relation to risk assessment by the score.

In conclusion, the current study validates the CARG risk score in predicting for grade 3-5 toxicities in Indian older adult cancer patients receiving curative intent chemotherapy. The

score contributes to informed clinical decision making with regard to planning treatment and expectation of toxicity in this cohort of patients. Additionally, indices such as ECOG PS and Charlson Comorbidity Index are inadequate to predict for toxicities and should only be used along with other measures to predict for chemotherapy related toxicities.

References :

1. Marosi C, Köller M. Challenge of cancer in the elderly. *ESMO Open*. 2016 Apr 1;1(3): e000020.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin*. 2010 Oct;60(5):277–300.
3. Patil VM, Chakraborty S, Dessai S, Kumar SS, Ratheesan K, Bindu T, et al. Patterns of care in geriatric cancer patients – An audit from a rural based hospital cancer registry in Kerala. *Indian J Cancer*. 2015 Jan 1;52(1):157.
4. Zhao L, Leung L-H, Wang J, Li H, Che J, Liu L, et al. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. *BMC Pulm Med* [Internet]. 2017 Aug 15 [cited 2020 Jun 17];17. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556668/>
5. Edahyr B, Lind M, Karsera L, Mafi R, Wallace K, Howell G, et al. PUB068 The Applicability of Comorbidity Indices in Predicting Chemo toxicity in Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2017 Jan 1;12(1): S1487–8.
6. van Abbema DL, van den Akker M, Janssen-Heijnen ML, van den Bergmortel F, Hoeben A, de Vos-Geelen J, et al. Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review. *J Geriatr Oncol*. 2019 Jan 1;10(1):31–41.

- 1
2
3 7. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11.5 Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. *J Clin Oncol*. 2011 Sep 1;29(25):3457–65.
8. Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. *J Clin Oncol*. 2016 May 16;34(20):2366–71.
9. Nie X, Liu D, Li Q, Bai C. Predicting chemotherapy toxicity in older adults with lung cancer. *J Geriatr Oncol*. 2013 Oct 1;4(4):334–9.
10. Alibhai SMH, Aziz S, Manokumar T, Timilshina N, Breunis H. A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer. *J Geriatr Oncol*. 2017;8(1):31–6.
11. Yang C-C, Fong Y, Lin L-C, Que J, Ting W-C, Chang C-L, et al. The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices. *Eur J Cardiothorac Surg*. 2018 Jan 1;53(1):235–40.
12. Noronha V, Talreja V, Joshi A, Patil V, Prabhash K. Survey for geriatric assessment in practicing oncologists in India. *Cancer Res Stat Treat*. 2019 Jul 1;2(2):232.
13. Noronha V, Ramaswamy A, Dhekle R, Talreja V, Gota V, Gawit K, et al. Initial experience of a geriatric oncology clinic in a tertiary cancer center in India. *Cancer Res Stat Treat*. 2020 Jul 1;3(2):208.
14. Moth EB, Kiely BE, Stefanic N, Naganathan V, Martin A, Grimison P, et al. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the

CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. *J Geriatr Oncol.* 2019;10(2):202–9.

15. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. *Cancer.* 2012;118(13):3377–86.

16. Zhang J, Liao X, Feng J, Yin T, Liang Y. Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology. *Oncol Lett.* 2019 Oct 31;18(5):4947–55.

Figure legends:

Figure 1- CARG (A) vs. (B) ACCI vs. (C) ECOG PS predict Grade 3 to 5 toxicity

Tables

Table 1 - Baseline characteristics of patients

Characteristic	Current study Number (%) (n=270)	CARG training cohort (n=500)
Mean age in years (range)	69 (65-83)	73 (65-91)
Gender		
• Female	121 (45)	281 (56)
• Male	149 (55)	219 (44)

Comorbidities		
<ul style="list-style-type: none"> Hypertension Diabetes mellitus Coronary artery disease Chronic kidney disease 	<p>114 (42)</p> <p>71 (26)</p> <p>12 (4)</p> <p>3 (1)</p>	<p>52%</p> <p>-</p> <p>20%</p> <p>-</p>
Number of comorbidities		
<ul style="list-style-type: none"> 0 1 >=2 	<p>125 (46)</p> <p>95 (35)</p> <p>50 (19)</p>	<p>10%</p> <p>-</p> <p>-</p>
Cancer stage		
<ul style="list-style-type: none"> Stage I-III 	270 (100)	191 (38)
Undergone resection	210 (78)	-
ECOG performance status (clinician assessed)		
<ul style="list-style-type: none"> 0/1 2 	<p>230 (85)</p> <p>40 (15)</p>	<p>402 (80) *</p> <p>86 (17) **</p>
Factors assessed in CARG		
<ul style="list-style-type: none"> Age \geq 72 years Cancer type GI or GU Chemotherapy dosing, standard dose No. of chemotherapy drugs, polychemotherapy Hemoglobin < 11 g/dL (male), < 10 g/dL (female) Creatinine clearance < 34 mL/min Hearing, fair or worse No. of falls in last 6 months, 1 or more IADL: Taking medications, with some help/unable MOS: Walking 1 block, somewhat limited/limited a lot MOS: Decreased social activity because of physical/emotional health, limited at least sometimes 	<p>60 (22)</p> <p>212 (79)</p> <p>205 (76)</p> <p>194 (72)</p> <p>99 (37)</p> <p>5 (2)</p> <p>19 (7)</p> <p>18 (7)</p> <p>29 (11)</p> <p>17 (6)</p> <p>18 (7)</p>	<p>270 (54)</p> <p>185 (37)</p> <p>380 (76)</p> <p>351 (70)</p> <p>62 (12)</p> <p>44 (9)</p> <p>123 (25)</p> <p>91 (18)</p> <p>39 (8)</p> <p>109 (22)</p> <p>218 (44)</p>
Median overall risk score	6	7
Risk stratification		
<ul style="list-style-type: none"> Low risk (0-5 points) Intermediate risk (6-9 points) High risk (10-19 points) 	<p>72 (27)</p> <p>164 (61)</p> <p>34 (13)</p>	<p>128 (26)</p> <p>227 (45)</p> <p>109 (22)</p>
Age adjusted Charlson's Comorbidity Index		
<ul style="list-style-type: none"> \leq4 >4 	<p>111(41)</p> <p>159(59)</p>	<p>-</p> <p>-</p>

*equivalent to KPS \geq 80; ** equivalent to KPS 60-70

Table 2 – Treatment related Grade 3 – grade 5 toxicities

Toxicity type	Grade 3 (%)	Grade 4 (%)	Grade 5 (%)
Haematological			
Anemia	14 (5)	0	0
Neutropenia	18 (7)	8(3)	0
Thrombocytopenia	6 (2)	1 (0.4)	0
Febrile neutropenia	12 (4)	2 (0.7)	3(1)
Cumulative haematological	46 (17)	11 (4)	3(1)
Non-haematological			
Diarrhoea	16 (6)	4 (2)	3(1) *
Vomiting	12 (4)	1(0.4)	1(0.3) **
Mucositis	10 (4)	0	
Constipation	1 (0.4)	0	
Hand-foot-syndrome	1 (0.4)	-	

Neuropathy	3 (1)	-	
Infection with normal ANC	47 (17)	7(3)	
Hyponatremia	8 (3)	2 (0.7)	
Fatigue	24 (9)	-	
Sudden cardiac death			4(1)
Cumulative non-haematological	99(37)	13(5)	8(3)
Cumulative (all toxicities)	119(44)	22(8)	11(4)

*All 3 patients developed dehydration with resulting acute renal failure. **Patient developed grade 4 vomiting with irreversible grade 4 hyponatremia resulting in death


Table 3 - Ability of CARG Risk Score Versus Physician assessed ECOG PS Versus Age adjusted Charlson's Comorbidity Index (ACCI) to Predict Grade 3-5 Chemotherapy Toxicity

Risk Stratification	No toxicity		Toxicity		p value
	Number	%	Number	%	
CARG risk score					0.001
• Low	42	58	30	42	
• Intermediate	81	49	83	51	
• High	7	21	27	79	
Physician assessed ECOG PS					0.69
• 0	5	56	4	44	
• 1	108	49	113	51	
• 2	17	43	23	57	

Age adjusted Charlson's Comorbidity Index					
• ≤4	55	50	56	50	0.7
• >4	75	47	84	53	

For peer review only

Figure 1 – Ability of CARG risk score (A) versus (B) Age adjusted Charlson Comorbidity Index (ACCI) versus (C) ECOG Performance Status Index to predict Grade 3 to 5 chemotherapy toxicity.



Supplementary table 1 – Details of chemotherapy

Chemotherapy regimens	Number (percentage)
Platinum containing regimens	159(59)
Oxaliplatin containing regimens	123 (46)
• Docetaxel-Oxaliplatin- 5 -fluorouracil	50 (19)
• Capecitabine-Oxaliplatin	26 (10)
• 5-fluorouracil - leucovorin-oxaliplatin	33 (12)
• 5-fluorouracil - leucovorin-oxaliplatin-irinotecan	1 (0.4)
• Epirubicin- Capecitabine-Oxaliplatin	10 (4)
• Gemcitabine-Oxaliplatin	2 (1)
• Epirubicin- Oxaliplatin - 5-fluorouracil	1 (0.4)
Cisplatin containing regimens	19(7)
• Gemcitabine-Cisplatin	19 (7)
Carboplatin containing regimens	17 (6)
• Paclitaxel- Carboplatin	6 (2)
• Carboplatin monotherapy	11 (4)
Non-Platinum containing regimens	111(41)
• Epirubicin – Cyclophosphamide	9 (3)
• Adriamycin – Cyclophosphamide	19 (7)
• Docetaxel – Cyclophosphamide	1 (0.4)
• Cyclophosphamide-methotrexate – 5-fluorouracil	1 (0.4)
• 5-fluorouracil/leucovorin monotherapy	10 (4)
• Capecitabine monotherapy	25 (9)
• Gemcitabine monotherapy	26 (10)
• Paclitaxel - Trastuzumab	9 (3)
• Paclitaxel monotherapy	3 (1)
• Docetaxel - 5-fluorouracil	5 (2)
• Gemcitabine- nab-Paclitaxel	2 (1)
• Gemcitabine Capecitabine	1 (0.4)
Chemotherapy timing	
• Neoadjuvant	5 (2)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

• Adjuvant	178 (66)
• Perioperative (neoadjuvant and adjuvant)	87 (32)

Supplementary table 2 – Treatment- related Grade 1 – grade 2 toxicities

Toxicity type	Grade 1/2 toxicities (%)
Hematological	
Anemia	148(55)
Neutropenia	52(19)
Cumulative hematological	160(59)
Non-hematological	
Diarrhoea	131(49)
Vomiting	140(52)
Mucositis	57(21)
Constipation	41(15)
Hand-foot-syndrome	59(22)
Neuropathy	75(28)
Hyponatremia	17(6)
Fatigue	197(73)
Cumulative non-hematological	230(85)
Cumulative (all toxicities)	234(87)

Supplementary table 3 - Ability of individual factors in the CARG risk score to predict for Grade 3 to 5 toxicities

Risk factor	Prevalence		Toxicity		p value	OR (95% CI)
	Number	%	Number	%		
Age \geq 72 years	60	22	34	57	0.4	1.28 (0.72-2.29)
Cancer type (GI or GU)	212	79	116	55	0.07	1.71 (0.95-3.08)
Chemotherapy dosing, standard dose	201	74	101	50	0.37	0.77 (0.45-1.35)
Polychemotherapy	194	72	106	55	0.14	1.48 (0.87-2.54)
Hemoglobin $<$ 11 gm% (male), $<$ 10 gm% (female)	99	37	65	66	0.001	2.45(1.47-4.09)
Creatinine clearance $<$ 34ml/min	5	2	3	60	0.71	1.4(0.23-8.52)
Hearing, fair or worse	19	7	10	53	0.94	1.03(0.41-2.63)
No. of falls in last 6 months, \geq 1	18	7	10	56	0.75	1.17(0.45-3.07)
IADL, taking medications, with some help/unable	29	11	17	59	0.44	1.336 (0.62-2.97)
MOS, walking 1 block equivalent, somewhat limited/limited a lot	17	6	11	65	0.27	1.76 (0.63-4.91)
MOS, decreased social activity because of physical/emotional health, limited at least sometimes	18	7	12	67	0.19	1.94(0.71-5.32)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	6
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	9
Objectives	3	State specific objectives, including any prespecified hypotheses	10
Methods			
Study design	4	Present key elements of study design early in the paper	10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	10
		(b) For matched studies, give matching criteria and number of exposed and unexposed	10
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11
Bias	9	Describe any efforts to address potential sources of bias	12
Study size	10	Explain how the study size was arrived at	12
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	12
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	12
		(b) Describe any methods used to examine subgroups and interactions	12
		(c) Explain how missing data were addressed	12
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			13

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	13
		(b) Give reasons for non-participation at each stage	13
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13
		(b) Indicate number of participants with missing data for each variable of interest	13
		(c) Summarise follow-up time (eg, average and total amount)	13
Outcome data	15*	Report numbers of outcome events or summary measures over time	14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14
Discussion			
Key results	18	Summarise key results with reference to study objectives	15
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	5

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.